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This study explored the factors that would maximally facilitate the binding of encapsulated 
neutral dendrimers to protein. The study had two aims. Firstly, to identify the factors that would 
achieve best encapsulation of the linear chain; factors included hydrophobicity and varying the 
length number of hydrogen bonds in the linear chain e.g. one H-bond (1HB-LC), two H-bonds 
(2HB-LC) and three H-bonds (3HB-LC). Secondly, the study aimed to establish how binding 
was moderated by functionalising the linear chains with various amino acids. 
Due to its water-soluble quality, PAMAM neutral dendrimer was chosen as the scaffold to 
create a functionalised linear chain. This was important as it meant the ligand and protein were 
in the same phase. Even more importantly, the terminal groups on the dendrimers were neutral 
and inert, thus ensuring that in the absence of any encapsulated functionality, there was no 
prospect of the dendrimers binding or interacting with binding surface of the protein. In this 
situation, only those dendrimers that had been functionalised with linear chains were able to 
bind. Using different numbers of hydrogen bonds, each hydrophobic linear chain had a terminal 
amino acid that used H-bonds and hydrophobic interactions to bind to the inside of the 
dendrimer. To create a surface functionalised system, multiple diverse linear chains were 
synthesised and incorporated into dendrimers. The encapsulation of 2HB-LC-Tyr or 2HB-LC-
Val in the dendrimer resulted in a 10-nm bathochromic shift in λmax; for 3HB-LC-Tyr and 
3HB-LC-Val the bathochromic shift was 5 nm. This finding is expected, because the water that 
solvates the linear chains is being replaced by the interior groups of the dendrimer. The extent 
of encapsulation is influenced by the number of hydrogen bonding sites present on the chain; 
those sites capable of forming three H-bonds, resulted in superior encapsulation than those with 
two H-bonds. The postulated mechanism for complexes to form is a collaborative relationship 
between f H-bonds and hydrophobic interactions. 3HB-LC-Tyr demonstrated the highest 
binding affinity, exhibiting an inhibition constant (Ki) of 1.23 µM; in contrast, the Ki of 2HB-
LC-Tyr, was 1.51 µM. 3HB-LC-Tyr bound most strongly of the different amino acids that were 
used to functionalise the the non-binding dendrimer (G3.5-OH). The mechanism for this is 
attributed to polyvalent interactions occurring between the surface of the Chy and the amino 
acids. Apart from the valine-functionalised dendrimer, which failed to bind, all of the 
compounds were competitive inhibitors,  
The study’s attention was turned next to cytochrome-c. To explore this, the non-covalent 
methodology that had been applied to α-chymotrypsin binding was used. Encapsulated 
tetrahydroxyphenyl porphyrin (THPP) was applied as an internal quench, facilitating direct 
measurement of binding. Zinc was added to THPP, enabling the dendrimer’s internal amines 
to coordinate to THPP. The results reveal that no binding took place for valine and non-
functionalised dendrimers, and the dissociation constant (Kd) of 3HB-LC-Tyr was 5.55 nm. 
These findings indicate that this method can be used to prepare libraries of dendrimer scaffolds, 







PAMAM  Poly(amido amine) 
PAMAM-OH Neutral Hydroxyl Terminated PAMAM 
PAMAM-COOH Acid Terminated PAMAM 
DCC Dynamic combinatorial chemistry  
DCLs Dynamic combinatorial libraries 
DCM Dichloromethane  
DCCI Dicyclohexyl carbodiimide 
DCU  Dicyclohexyl urea 
DMSO  Dimethylsulphoxide  
EDA  Ethylenediamine  
EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide  
DMAP  4-Dimethylaminopyridine  
MA Methyl Acrylate 
BTNA N-benzoyltyrosine-p-nitroanilide 
1H NMR Proton Nuclear Magnetic Resonance Spectrometry 
13C NMR Carbon-13 Nuclear Magnetic Resonance Spectrometry 
IR/FTIR  Infra Red/Fourier Transfer Infra Red Spectrometry 
ES-TOF MS Electron Spray Time-Of-Flight Mass Spectrometry 
MALDI-TOF MS Matrix Assisted Laser Desorption Ionisation Time of Flight  
Chy  α-chymotrypsin 
Cyt-c  cytochrome-c 
NaOH Sodium Hydroxide 
K2CO3 Potassium Carbonate 
TRIS Tris(hydroxymethyl)aminomethane 
UV/Vis Spectrometry Ultra Violet/Visible Spectrometry 
Ɛ Extinction coefficient  
nm Nanometre.  
DLS Dynamic light scattering  
TRIS Tris(hydroxymethyl)aminomethane.  
THPP Tetra-4-hydroxyphenyl porphyrin.  
ZnTHPP Zinc-tetra-4-hydroxyphenyl porphyrin. 
1HB-LC-Boc-Tyr   One hydrogen bonding of linear chain with Boc Tyrosine 
1HB-LC-Tyr  One hydrogen bonding of linear chain with  Tyrosine 
2HB-LC-Boc-Tyr   Two hydrogen bonding of linear chain with Boc Tyrosine 
2HB-LC-Tyr  Two hydrogen bonding of linear chain with  Tyrosine 
2HB-LC-Boc-Val  Two hydrogen bonding of linear chain with Boc Valine 
2HB-LC-Val  Two hydrogen bonding of linear chain with Valine 
3HB-LC-Boc-Tyr   Three hydrogen bonding of linear chain with Boc Tyrosine 
3HB-LC-Tyr  Three hydrogen bonding of linear chain with  Tyrosine 
3HB-LC-Boc-Val  Three hydrogen bonding of linear chain with Boc Valine 
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1.0  Introduction to Protein-Protein Interactions 
When proteins interact with other proteins, protein-protein complexes are formed. These 
complexes can be categorised into the following groups: firstly, homocomplexes, which are 
characterised by their stability and durability; and secondly, heterocomplexes, which – despite 
potentially being durable – can be strongly affected by external factors.1 Hence, the existence 
of heterocomplexes depends on the presence of a protein that is not dependent on something 
else for its own existence. Protein-protein complexation plays a fundamental role in almost all 
biological processes. Examples include signal transduction, cytoskeletal remodelling, cell 
regulation, and others.2 In view of this, the interaction of a pair of proteins occurs systematically 
and non-randomly. The protein-protein association is organised and regulated in a detailed 
manner, the purpose being to achieve a specific objective.3 
As noted previously, protein-protein interactions are critically important to for the biological 
functions that sustain life. These biological processes include protease-inhibitor complexes, 
antibody-antigen complexes, and hormone-receptor complexes. In these particular cases, the 
complexes have been extensively studied and comprehended, but there are a great many 
complexes that have yet to yield to modern scientific inquiry. At the same time, irregular 
protein-protein interactions have been identified, which are implicated in the pathogenesis and 
pathophysiology of a range of diseases. For example, sickle cell anaemia results from the 
oligomerisation of mutant haemoglobin, which emphasises the potentially negative effects of 
unwanted protein-protein interactions.4 Additionally, protein-protein interactions with a lower 
level of specificity have been identified in the literature, which occur when proteins give rise 
to aggregates. A range of diseases, including Alzheimer’s and various types of rheumatoid 






1.1 Protein-Protein Binding Interface 
 
Given the prominence of protein-protein interactions in various types of biological process, 
researchers have naturally developed an interest in understanding them and, moreover, 
controlling them. To produce molecules that interfere with protein-protein interactions, 
however, it is necessary to understood protein-protein binding interfaces.6 It is possible to 
consider the protein-protein interface a specific surface that is available on each of the proteins 
in the pair, which are no longer accessible upon interaction, and which are principally 
hydrophobic.7 
Protein-protein complexation is marked by conformational alterations, and researchers have 
devised a range of models to account for the mechanism of action. Fischer’s “lock and key” 
model, proposed in 1894, supposed that shape selectivity was the operating principle, which 
does not depend on conformational change. Nevertheless, this model fails to account for 
interactions of proteins with substances that do not have a uniform shape. In 1958, Koshland 
devised the “induced fit” model to account for this limitation. The model posits that the active 
site is slightly elastic, thus facilitating its accommodation of the ligand and, in turn, resulting 
in a conformational change. The final idea proposed regarding the protein-protein binding 
interface is that of a “pre-existing equilibrium”. The model suggests that the protein’s native 
site presents a collection of conformations at the active site, thereby creating a situation in 
which the ligand is drawn to an active conformation.8 
Due to cooperative binding that affords stability to molecule-molecule interactions, a strength 
obtains to the forces in combination that was not available when they were independent.5 A 




When apparent affinity increases, this reflects positive cooperation, which increases the 
likelihood that a second molecule is bound. It is reasonable to view this phenomenon as a 
substantial increase in the relative concentration of the ligand for the second binding.9 The 
results of cooperative binding are given in Figure 1. The first bond is established between the 
original binding site and the ligand at the rate of K1. Once this bond has been formed, the next 
interaction takes place at a faster pace and, alongside this, is stronger. This is because the 
second ligand’s relative concentration is greater than those of the other molecules. 
Additionally, K1 is significantly smaller than K2, meaning that the impact is non-additive. 
Noteworthily, cooperative binding is associated with a greater additive effect.10 
 
 
Figure 1: Impact of cooperative binding, where K2 is significantly greater than K1 
 
The complexity of the mechanism that underpins protein-protein interactions stems from the 
expansive surface area involved. Additionally, hydrophobicity and electrostatics perform a 
critical function. Ultimately, viable interactions are the result of the collaborative impacts of 
countless parameters.11-12 The specificity of the mechanism is significant, where proteins select 
other proteins with a similarly sized interfacial area, which has a three-dimensional shape. 
Additionally, intermolecular forces are taken into account, as well as the locations of the amino 
acids. Figure 2 provides a simplified overview of the mechanism involved in protein-protein 







Figure 2: Partner selection mechanism in protein-protein interaction 
 
The processes and details that underlie protein-protein interactions have yet to be clarified in 
the literature. In the studies conducted by Bogan and Thorn, the researchers drew on alanine 
screening and kinetic and thermodynamic measurements to illuminate the issue.12 In particular, 
the researchers sought to identify the contribution of specific residues to the key binding region 
(i.e., the “hot spot”, an idea proposed by Clackson and Wells, which itself stemmed from the 
observation of free energy of binding consisting of a restricted region of amino acid residues).13 
As Bogan and Thorn recognised, the residues within the key binding region perform a critical 
function in the degree to which the protein complex is stable. 12 Hence, the key binding region 
plays a key role in the protein-protein interface. 
Further, Bogan and Thorn indicated that the key binding regions of binding energy are situated 
proximal to the interface’s centre, while the residues situated at the interface do not play a role 
in binding.12 Additionally, findings indicated that residues in the area surrounding the key 
binding area probably operate by ensuring that bulk solvent does not contact the interacting 
residues. The literature indicates that the separation between bulk solvent and interacting 
residues is a prerequisite for successful protein-protein interactions. Additionally, Bogan and 







are enriched with the following types of amino acid, each of which has a proportion of greater 
than 10%: firstly, tryptophan (21%), tyrosine (12.3%), and arginine (13.3%). Given the non-
random nature of the amino acid composition in key binding regions, preference towards 
specific amino acids was discerned in terms of the high-energy interactions between two 
particular proteins in a heterodimer. 12 
The density of certain amino acids within the binding interface is greater than the density 
associated with other regions of the protein molecule. Compared to the exterior of the molecule, 
amino acids of this kind are associated with a greater level of hydrophobicity. As a 
consequence, it is possible to improve the binding interactions that occur between the proteins 
by capitalising on hydrophobic interactions. Additionally, large aromatic amino acids are 
typically preferred at the binding interfaces, while the binding surface is the protein region 
associated with the greatest likelihood of containing amino acids such as tyrosine.7-8 Table 1 
presents possible target proteins for evaluating the binding capability of polymers, as well as 
the capacity to differentiate between protein surfaces in a specific enzyme family. When 
interactions between synthetic inhibitors and proteins are disrupted, this relies on the 
emergence of robust affiliated synthetic subunit molecule and protein complexes, which 










Mechanism Protein Amino acid 
residue 
Inhibitor Cleavage site 
Serine protease Elastase 240 α-anititrypsin Ala, Gly 




Kallikrein 619 Aprotinin Arg 
Thrombin 308 Argatroban Arg 




Phe, Trp, Leu 
Aspartate 
protease 
Cathepsin D 346 Pepstatin A Phe-Phe 
 
Table 1: Enzymes based on their cleavage site and standard inhibitor 
 
Investigating protein structures in this way offers insights into the manner in which protein-
protein interactions operate. Equipped with this understanding, it is possible to begin 
investigating the design and delivery of novel synthetic agents that could disrupt undesirable, 
disease-causing interactions. 
 
1.2 Inhibiting Protein-Protein Interactions 
 
Owing to the critical part they play in biological processes and systems, protein-protein 
interactions, when interfered and disrupted, can point the way towards novel therapeutic agents. 
Developments have occurred in recent years in the studies that have examined synthetic agent 
design for disrupting protein-protein interactions. Moreover, substantial amounts of research 
have been directed towards the issue of designing molecules with varying molecular weights 
that can inhibit protein-protein binding.14 
Non-covalent interactions, including hydrophobic effects, electrostatic interactions, Van der 
Waals forces, and hydrogen bonding, succeed when protein-protein complexes are formed.15 




protein-protein binding: targeting the protein’s interior active site, which is not exposed to the 
bulk solvent; and targeting the protein’s exterior surface, which is not isolated from the bulk 
solvent.16 
 
1.3 Protein-Protein Inhibition With Low Molecular Weight Synthetic 
Agents 
 
1.3.1 Small Molecule Inhibitors 
 
Most pharmaceutical studies in this field have sought to design small molecules for the 
inhibition of protein-protein interactions. 17 In many research projects, the aim has been to 
design small molecules that can interact with a specific site in the enzyme or the enzyme’s 
active site. The predominant interactions within a protein’s active site are electrostatic 
interactions, hydrogen bonding, and salt bridges. Resultantly, small “drug-like” molecules, 
which display hydrogen bond donor groups and hydrophilic features, have been associated with 
potential efficacy.18 Nevertheless, a range of obstacles must be overcome when designing 
therapeutic agents that address a protein-protein interactions. For example, the region needed 
for recognition is substantial in size (i.e., from 700-1500Å2 per protein),19 which is problematic 
for small molecule inhibitors. Additionally, interacting surfaces have been identified as cavities 
with a high level of shallowness, and which do not have specific features. As such, selective 
targeting is a complex affair. 20 
Yet another challenge relates to the nature of the binding region of the two proteins involved 
in the protein-protein interaction. Often, the binding site is considered non-contiguous, the 
implication being that mimicry with simple synthetic peptides would not achieve the goal.21 
Additionally, dissimilar to enzyme-ligand interactions, the surfaces involved in protein-protein 




having a “pocket” that its counterpart occupies, each of the proteins can have protruding areas 
and “sub-pockets”, which poses substantial challenges for inhibitor design.22 Moreover, 
regarding the use of small molecules as possible drug molecules, they must have efficacy in 
vivo. Aside from needing to display sufficient effectiveness in relation to the target protein, it 
is necessary for them to satisfy toxicity and bioavailability demands. Generally speaking, 
molecules with these “drug-like” features tend to have molecular weights that are not higher 
than 500.23 
In the 1990s, the design of small molecule inhibitors experienced noteworthy strides forward. 
Quershi et al., in 1999, established a non-peptide antagonist (Figure 3), which was identified 
based on screening a chemical library of inhibitors of human erythropoietin, binding to the 
erythropoietin receptor’s extracellular region. This resulted in the identification of a derivative 
of biphenyl indole, which was associated with considerable efficacy as an inhibitor. The 




Figure 3: Chemical structure of non-peptide erythropoietin antagonist 
 
In the study conducted by Tilley et al.,27 the researchers found small molecules that could serve 




important function in growth activation and T cell differentiation.28 At the outset, the small 
molecule (see Figure 4a) was established to imitate arginine and phenylalanine side chains of 
IL-2, which is implicated in binding to the α subunit of the IL-2 receptor (IL-2Rα). Although 
the molecule’s value as a mimic was non-existent, further investigation revealed that it was a 
strong IL-2 inhibitor, binding to its receptor.29-31 As such, this discovery was the first case in 
which a small molecule had been identified that could inhibit protein-protein interactions, in 
which the inhibitor bound to the protein partner rather than the receptor. In Braisted et al.’s 
study,32 the scholars developed this research project to establish an analogue with even greater 
potency (Figure 4b). The IC50 of this compound was 60 mM, and it bound to IL-2 with a 1:1 
stoichiometry and a Kd amounting to 100 nM. Building on this work, Waal et al. established a 
nonpeptidic, potent inhibitor (Figure 4c).33 These researchers drew on a chemical alteration of 
the previous analogues to promote the capacity of the inhibitor. Experimental evidence 
revealed that the furanoic acid incorporation led to an enhancement in the inhibitor’s activity 







Figure 4: Small molecule inhibitors of IL-2 and IL-2Rα interaction. (a) acylphenylalanine-
based compound83 (b-c) chemically-altered derivatives of compound a. 
 
A notable protein target is inducible nitric oxide synthase (iNOS). As a molecule that plays a 
critical function in signal transduction, and which is produced by the dimeric enzyme nitric 
oxide synthase, nitric oxide’s inducible isoform, iNOS, is implicated in tissue damage in 
various autoimmune diseases. An inhibitor designed to address iNOS, therefore, is associated 
with considerable clinical value. In view of this, McMillan et al. sought to establish an iNOS 
inhibitor by leveraging combinatorial chemistry ( Figure 5). Perturbation of the dimerization 




was noted that the inhibitor operates by interrupting dimer formation, where these operation is 
dependent on an allosteric mechanism. Drawing on a rat model, the in vivo studies indicated 
that the inhibitor showed activity with ED50 values of less than 2 mg/kg. The results indicate 




Figure 5: Chemical structure of iNOS 
 
Tumour necrosis factor alpha (TNF-α), a member of the cytokine family that is implicated in 
inflammatory conditions, is another prominent target. Research into the direct inhibition of 
TNF-α has identified a range of inhibitory antibodies, including Enbrel, Humira, and 
Remicade, several of which have been identified as efficacious for rheumatoid arthritis 
treatment.80 Nevertheless, small molecule inhibitors are preferable as a result of their cost-
effectiveness and the advantageous method of delivery. In the study conducted by He et al.,87 
the researchers developed a strong TNF-α inhibitor, the chemical structure of which is 
illustrated in Figure 6. This inhibitor leads to the displacement of a subunit of the biologically 







Figure 6: Chemical structure of TNF-α small molecule inhibitor 
 
1.3.2 α-Helix Mimetics 
 
A notable development took place in this area of study when researchers identified the critical 
function played by helical segments in various protein-protein interactions. In view of this, 
helical mimics synthesis was identified as a way to develop new treatments for a range of 
conditions.88 The literature indicates that around 15% of the protein data bank, as of August 
2009, comprised protein-protein complexes. Additionally, 62% of these complexes contained 
a helix at the interface. With this in mind, it is clear that α-helices are highly-consequential for 
protein-protein interactions.89 In Restorp and Rebek’s study, the researchers provided an 
account of the synthesis of a series of heterocyclic piperazine-based scaffolds (Figure 7). These 
scaffolds could mimic the i, i+4, i+8, and i+11 side chains of an α-helix. It is possible to use 
the general synthetic process identified to synthesise α-helix mimetics, and to tailor these to a 
particular interaction. The design of the compounds was intended to mimic the amphiphilic 
nature of α-helices, and this was achieved by drawing on a hydrophilic surface for hydrogen 






Figure 7: Chemical structure for the skeleton of several heterocyclic piperazine-based 
scaffolds 
 
Therapeutic interventions for cancer patients also rely on protein-protein interaction inhibitors. 
P53, the tumour suppressor protein, has been identified as a notable transcription factor that 
safeguards cells from adverse transformations. Additionally, hDM2 regulates the activity and 
level of P53, the overexpression of which will undermine protein function.31 The interaction 
between P53 and hDM2 incorporates the following hydrophobic residues from the tumour 
suppressor protein, thereby coordinating a helical conformation to a hydrophobic cleft that is a 
feature of hDM2: namely, Phe19, Trp23 and Leu26.32-34 In view of this, a hDM2-P53 
interaction can lead to protein stabilisation, thereby pointing the way towards a novel 
intervention for cancerous conditions. In the study conducted by Vassilev et al.,35 the 
researchers devised a small molecule inhibitor which coordinates hDM2 inside the binding 
pocket of P53, thereby resulting in the activation of its pathway in cancer cells. Nude mice 
studies indicated that the outcomes included apoptosis, cell arrest, and inhibition of the growth 
of human tumour xenografts. X-ray crystallography research indicated that hDM2 is marked 
by a deep cavity, which contains side chains from the peptide’s helical region. The small 




Nutlins. Following chemical optimisation, Nutlin-3 was established (see Figure 8), and it was 
identified as an inhibitor of hDM2-P53 complexes. In particular, it was associated with IC50 




Figure 8: Chemical structure of Nutlin-3 
 
Due to the finding that protein-protein interaction inhibitors are associated with potential 
clinical value in cancer treatment and management, many studies were conducted that focused 
on disrupting this specific interaction. For example, Plante et al.’s research was concerned with 
identifying oligobenzamide proteomimetic inhibitors. As mentioned above, Phe19, Trp23, and 
Leu26 are the main residues that are identified at the hDM2-P53 complex interface. A critical 
strategic approach in scaffold design for a helical mimic is that the scaffold must have the 
capacity to imitate the residues at the P53 helix’s i, i+4, and i+7 side chains. Oligobenzamide, 
which is illustrated in Figure 9, was one of the compounds that came from this research 
initiative, and it was placed on top of the face of the P53 helix. Clearly, O-alkyl substituents of 
the amino terminated tri-benzamide are lying on a single face and, moreover, mimic the spatial 
orientation of the α-helix’s i, i+4, and i+7 residues. On the basis of these findings, it is clear 







Figure 9: Chemical structure of oligobenzamide proteomimetic inhibitor 
 
As previously noted, the synthesis of a nonpeptidic small molecule α-helical mimic, which can 
serve as an inhibitor of protein-protein interactions, has long been an active area of research in 
the literature. Lee et al. sought to synthesise a novel pyrrolopyrimadine-based receptor, which 
is illustrated in Figure 10. The capacity of this scaffold for interrupting the P53-MDMX 
interaction was examined by the researchers, thereby informing its potential efficacy as an α-
helical mimic. At the outset, the researchers screened the scaffold using a 900-compound 
library, and primary amines containing hydrophobic groups were chosen. Noteworthily, the 
hydrophobic groups played a critical role in facilitating the mimicry of the side chains of the 
amino acids identified in P53. The features of this scaffold include conformational rigidity, cell 
permeability, and positive aqueous stability. Additionally, the synthetic route is 
straightforward, as a consequence of which the synthetic process complies with the 
establishment of expansive libraries and elevated throughput screening. Resultantly, the 
scaffold is associated with considerable promise as a way in which to discover comparable 







Figure 10: Chemical structure of pyrrolopyrimadine-based receptor 
 
The reader should note that the information presented throughout this section is by no means 
comprehensive. Other, more exhaustive, articles have been published on protein-protein 
interactions with nonpeptidic small molecule α-helix mimetics.36 
 
1.3.2 Porphyrin and Calixarene Based Receptors 
 
Since designing small molecule inhibitors is a complex affair, scholars have also sought to 
examine the efficacy of large scaffold molecules as protein binding agents. As noted earlier, 
designing synthetic agents to bind an active site is a highly-active area of research. 
Nevertheless, a different approach for disrupting protein-protein association involves binding 
to the surface of a protein that is near to the active site but not within it directly.36 The peripheral 
surface is unique for every protein, and it contains hydrophilic, hydrophobic, and charged areas. 
Additionally, the interface between a pair of connecting proteins involves hydrogen bonding, 




Most of the molecules that have been examined in the literature achieve the disruption of 
interactions by binding within active cavities on proteins. As a result, relatively few studies 
have sought to investigate synthetic molecules that intervene in the functioning of a protein 
through binding to the external surface. Studies in this area could promote the design of novel 
agents and, at the same time, aid in understanding the periphery of proteins and the mechanisms 
associated with surface recognition.35 
Fischer et al.’s 1985 study reported on evidence that a tetracarboxyphenyl porphyrin, which is 
illustrated in Figure 11, was a corresponding topological mimic for cytochrome-c, and that it 
would bind with a Kd of 5 µM.
36 As an electron transport protein that has been identified in 
horse heart, cytochrome-c is a protein that has been studied more extensively than most others 
in the literature. It is regarded as a viable target, and it performs a crucial function not only in 
apoptosis but also in electron transfer. The haem edge’s surface contains a collection of 
arrangements of cationic lysine residues and hydrophobic domains, thereby indicating a high 
level of dependence, particularly in terms of electrostatic interactions.37 
 
 





Hamilton et al. extended this body of research by examining tetraphenyl porphyrin scaffolds 
and calyx[4]arene scaffolds, drawing on several techniques (e.g., fluorescence spectroscopy).38 
The researchers’ strategy involved leveraging a macrocyclic scaffold, on which the peptide 
loops could be attached using covalent bonds. Following this, a mimic of an antibody, grounded 
on calix[4]arene connected to four constrained peptide loops, was synthesised (Figure 12).39 
The rationale for selecting calix[4]arene stemmed from its accessibility and its ability to be set 
in a cone configuration, thereby meaning that para substituents would be propelled onto a single 
edge of the ring (and, in this way, creating a binding domain).40 
 
 
Figure 12: Chemical structure for an antibody mimic based on calix[4]arene scaffold and 
covalently attached to four peptide loops of the sequence (Gly-Asp-Gly-Asp) 
 
The first target protein employed in the study was cytochrome-c, which has been extensively 
investigated, well characterised, and identified as having a surface that is positively charged. 
The peptide loops consist of a sequence that is negatively charged (namely, Gly-Asp-Gly-Asp), 
the opposite charge being important for complementing cytochrome-c’s positively charged 




four lysine residues, the implication being that the coverage of the synthetic receptor extended 
to a significant surface of the protein. The results indicated that the receptor disrupted the 
formation of cytochrome c/cytochrome c peroxidase complex, confirming the X-ray findings.41 
In a subsequent study conducted by the same researchers, it was found that a comparable 
antibody mimic could interact with chymotrypsin surface, thereby facilitating the disruption of 
protease-proteinaceous inhibitor interactions.42 Calixarene receptors were identified as 
undesirable due to the complex synthetic procedures needed, as well as the negligible yields 
that resulted. Several studies have been conducted on other supramolecular scaffold-based 
receptors.43-44 
The same researchers, in 2000, published a study in which it was shown that cytochrome-c’s 
surface had the capacity to be recognised by a tetraphenyl porphyrin scaffold with a variety of 
amino acid and peptide derivatives around the outside edge (Figure 13).45 The results were 
indicative of the fact that the a receptor’s relative affinity to the protein surface was informed 
by the number of anionic and hydrophobic groups. The affinity of these receptors in terms of 
binding was elevated in an aqueous medium, and receptor 19 (see Figure 13) was associated 
with the greatest affinity with respect to the surface of cytochrome-c (Kd = 20 nM). 
Additionally, the study’s outcomes pointed the way towards the possible clinical value of 
receptor 19. Studies conducted prior to this one demonstrated that cytochrome-c has the 
capacity to interact with an apoptotic protease activating factor, namely APAF1.46 This 
particular interaction could trigger apoptosis. Hence, receptors of this kind were identified as 






Figure 13: Chemical structures for tetraphenyl porphyrin scaffolds for recognition of 
peripheral surface of cytochrome-c 
 
A protein’s peripheral surface plays a fundamental role in the mediation of protein-protein 
binding in various biological procedures, including cell growth and cell proliferation. In view 
of this, synthetic molecules that serve as complements to the structural characteristics of the 
protein periphery are anticipated to bind, thus disrupting the surface, rather than the active site 
of the enzyme. Hamilton et al.’s 2003 study found that a group of tetrabiphenyl porphyrin-
based receptors, particularly receptor 20 (see Figure 14), were associated with a heightened 
affinity with respect to the surface of cytochrome-c, exhibiting a Kd value of 0.6 nM. The 
researchers leveraged circular dichroism to examine the impact of coordination of this receptor 
in relation to the protein. Without the receptor, cytochrome-c’s melting temperature was 85 °C, 




of these results, other studies were conducted to examine the potential of porphyrin-based 
receptors for protein denaturation and protein surface recognition. Additionally, as an 
outgrowth of this study, Hamilton’s research group devised a sequence of metalloporphyrin 
dimers for the acceleration of proteolysis in cytochrome-c.46-47 
 
 
Figure 14: Chemical structure of tetrabiphenyl porphyrin-based receptor for surface 
recognition and improved unfolding of cytochrome-c 
 
Trauner et al.’s study, published in 2003, resulted in the development of a set of porphyrin-
based ligands associated with value for potassium channel surface recognition.48 The 
researchers revealed that the four-fold symmetrical molecules served as peptide toxin mimics, 
thereby binding to the channel’s four subunits. The result of the ligands binding to the 
potassium channels’ Kv1x class was the partial obstruction of conductance. Noteworthily, 
potassium channels facilitate the regulation of membrane potential and, furthermore, they are 
implicated in numerous cellular procedures. Hence, they are an attractive target for new drug 
development. The formulation of synthetic inhibitors could offer clinical solutions for a range 




set of porphyrin ligands were employed for competitive binding assays with 50 I-hongo-toxin1-
A19Y/Y37Ff. One of the functions of this toxin is to coordinate to the external vestibule of 
Kv1.3 channels. In the activation of human T-lymphocyte, this potassium channel, which is 
voltage-gated, plays a fundamental role. Studies indicate that the cationic ligands in Figure 15 
were associated with the most potent interactions with respect to the Kv1.3 channel. The 
cationic side chains were identified as having the ability to establish salt bridges to aspartate 
residues, which accounted for the high level of affinity. Additionally, in terms of their 
geometric features, ligands (a-c)-were viable for sufficient binding. As this research project 
attests to, developing a class of compounds of this kind has significant value for new drug 
development in various areas.49 
 
 
Figure 15: Chemical structures of several cationic porphyrin-based ligands for the potassium 







If the abovementioned obstacles are set aside for one moment, the reader may be motivated to 
reflect on the countless developments that have taken place in this field. In particular, it is 
noteworthy that there are many cases of synthetic ligands with a low molecular weight that 
have the capacity to facilitate the inhibition of protein-protein interactions. 
 
1.3.3 Supramolecular Protein Scaffold 
 
Determining what impact nanomaterials have on protein function and biophysical 
characteristics is crucial for bio-nanotechnological research. As protein molecules that are 
ubiquitous in all of the biological processes that underpin life, the function of enzymes is 
dependent on their structural integrity (at both the secondary and tertiary levels). It is 
unfortunate to note that enzymes can experience conformational change as a result of the 
disruption of the non-covalent interactions that promote their stabilisation (e.g., electrostatic 
interactions, Van der Waals forces, and hydrogen bonds). Additionally, protein molecules’ 
structural dynamics play a substantial role in regulating effective catalytic function, which has 
only been taken into consideration recently in research projects addressing the impact of 
nanomaterials on proteins. To give an example, protein dynamics are impacted in the event that 
the enzyme is attached in a covalent way to graphene oxide (GO) nanosheets. Recognition of 
substrate depends on the flexibility of the protein in view of the fact that it underpins 
conformational modifications at the substrate-binding region.45 Therefore, fluctuant protein 







Figure 16: Glycosylated bilirubin oxidase (BOD) immobilised onto GO nanosheets 
 
To facilitate surface recognition, Rotello drew on self-assembled systems as part of an 
approach that incorporated mixed-monolayer protected gold clusters (MMPCs), functionalized 
using terminal anionic groups. These anionic groups were made to bind to a positively charged 
α-chymotrypsin surface, the purpose being to restrict enzymatic activity by means of a two-
stage mechanism (i.e., rapid reversible suppression followed by a less rapid, gradual, and 




Scheme 1: MMPC use in surface recognition 
 
The researchers found that the electrostatic interactions were efficacious because the process 




the interaction between α-chymotrypsin and the gold nanoparticle took place based on circular 
dichroism spectroscopy. In this process, 10 nM Ki(app) and stoichiometry were used, 
consisting of five protein molecules for a single MMPC. Noteworthily, the selectivity of the 
mechanism of inhibition was higher for α-chymotrypsin than it was for β-galactosidase. 
Synthetic receptor and inhibitor of α-chymotrypsin activity were the functions of the surface 
carboxylate group. In particular, the level of α-chymotrypsin suppression was greater based on 
dose response (i.e., by weight) when compared to the other synthetic inhibitors.31 Wang et al. 
offered data to suggest that a nanocomposite material could be devised to facilitate new drug 
development to intervene in conditions such as Alzheimer’s, where this material would be 
based on GO and iron oxide (IO) integration.32 
Other possible protein inhibitors that are worth paying attention to are dendrimers, which are 
associated with terminal groups that enhance their interaction with the hot spot residue. Owing 
to the comparable sizes and contours of critical proteins, dendritic polymers are regularly 
referred to as artificial globular proteins.33 
 
1.4 Dendritic Polymer Synthesis 
 
1.4.1 Dendrimer Synthesis 
 
Flory’s 1952 paper initiated a new era in dendritic polymer chemistry.25 The researcher’s 
theory centres on a condensation between ABx (where x ≥ 2) monomer molecules. Vögtle et 
al.,3 building on this theory, proposed the initial iterative synthetic process for dendrimer 
synthesis, which was based on aliphatic amine AB2 type monomer molecules. Condensation 
engendered the synthesis of so-called “cascade” polymers.3 As monodisperse symmetrical 




achieved by a layered approach to dendrimer construction. As a complex synthesis process, a 
range of deprotection, protection, and purification phases are involved at every step of the 
process. The first synthesis processes were devised in 1978, and – at present – there are two 
broad categories: firstly, the divergent approach; and secondly, the convergent approach.   
 
1.4.2 Divergent Approach 
 
Divergent dendrimer synthesis, devised based on the branched model of Tomalia et al., begins 
with an initiator core, after which layers are added via sequences of coupling and activation 
stages to build outwards in the direction of the molecule’s periphery.26 The growth of a 
dendrimer using the divergent approach is illustrated in Figure 17. The terminal groups of every 
generation are reacted with the complementary reactive group on the monomer unit.27 Hence, 
branch points are created at every site, thereby leading to a growth in the amount of terminal 
functionalized groups. This is known as the coupling step. When the initial coupling stage has 
been completed, this is followed by an activation step, in which dormant functional groups are 
activated. This enables the monomer to react, thereby increasing generation.26 Noteworthily, 
the availability of active hydrogen available determines the number of branches in the 






Figure 17: Divergent dendrimer synthesis 
 
Divergent dendrimer synthesis benefits from its straightforward nature, as well as the fact that, 
when viable reaction conditions can be sustained and fitting reagents are employed, industrial 
scale synthesis is entirely achievable. Nevertheless, given the sequence of activation and 
coupling reaction phases required in this approach, the number of reactions required at the 
perimeter increases exponentially. Hence, to guarantee that each reaction step finishes as 
expected, a considerable excess of reagents is required. The manner in which the required 
amount of coupling reactions scales with every generation, as well as the likelihood of 
undesirable side-effects (and the resulting possibility of incomplete by-products), is another 
disadvantage. Additionally, the activating reagent must be eliminated completely to safeguard 
against the formation of unnecessary dendritic structures.27 
Polyamido amines (or “starburst” dendrimers), which were originally characterised by Tomalia 
et al. in 1985,26 were the initial family of dendrimers that were synthesised and, in turn, made 
commercially available. As an extensively studied family of dendrimers, further information 





1.4.3 Convergent Approach 
 
Fréchet and Hawker were the first researchers to document the convergent approach for 
dendritic polymer synthesis.6, 26, 31 The approach begins with the periphery of the final dendritic 
structure and proceeds towards the core, thereby creating a reactive dendron. To produce a 
globular dendritic architecture, a group of dendrons are reacted with a polyfunctional core 
molecule.28 Hence, convergent synthesis differs from divergent synthesis in that the core is 
included in the macromolecule at the ultimate reaction phase.32 The convergent approach is 
illustrated in Figure 18. 
 
 
Figure 18: Convergent dendrimer synthesis 
 
Following coupling, it is possible to use an activation process to trigger the dendron’s focal 
point. The architectural control associated with this approach is high because the process moves 
from the periphery towards the core, thereby meaning that a reduced number of coupling 
reactions are required at every phase. Hence, slight surplus reagents are needed, which 




the convergent approach is superior to the divergent approach stems from its capacity to 
distribute functional groups across the architecture selectively. As such, the approaches used 
to manufacture symmetrical or unsymmetrical dendrimers in this way benefit from accuracy 
and high levels of definition. In terms of the approach’s disadvantages, steric crowding may 
emerge due to the movement from the periphery to the interior. Large generation dendrimers 
are complex to produce, and defective structural features are common.12 Poly (benzyl ethers) 
are regularly produced using this approach, and they have been manufactured by Grayson and 
Fréchet.6, 32 
 
1.5 Concerns Surrounding Synthetic Inhibitors 
 
As previously noted, gaining insight into protein-protein interactions is vital for the 
advancement of research into the discovery of novel drug molecules and inhibitors.116, 117 
Owing to the sizeable nature of the interfacial areas that proteins have, identifying small “drug-
like” molecules that can serve as effective inhibitors has been a complex task. Nevertheless, 
significant progress has been made in recent years. As a case in point, studies have 
demonstrated that small molecules can, in fact, disrupt protein-protein interactions, thereby 
serving as effective inhibitors.118 Figure 19 illustrates the distribution of interfacial areas from 
common protein-protein complexes, as identified in the literature.77 The amount of complexes 
characterised by comparable binding areas are grouped into one region, after which they are 






Figure 19: Number of protein complexes found in the literature plotted against the size of the 
interfacial area 
 
As the figure above indicates, the coverage of protein complexes is broad, and so molecules 
with high molecular weights have been identified as synthetic protein-protein binding 
inhibitors that could be efficacious. Given the sizeable nature of a protein’s interfacial area, a 
critical issue is synthesising a sequence of macromolecular structures that can interact over 
several areas. Key variables that have strong implications for protein-protein interactions 
include three-dimensional shape, functionality, and the location of this particular functionality 
inside the interacting region. In view of this, the purpose of the present research project is to 
facilitate the synthesis of a sequence of macromolecular structures that satisfy these parameters. 
The first of the large molecules that are worthy of consideration are linear polymers, which 
have been studied in several research projects addressing the interaction between proteins and 
linear polymers. Bruening et al. published results attesting to the high capacity binding of 
































the immobilisation of several protein monolayers.119 Drawing on a nitro triacetate/copper 
complex ((NTA)-Cu2+), PAA brushes were derivatised, after which they displayed a capacity 
to bind to various proteins. The capacity of a protein to interact with a surface is potentially 
invaluable for protein purification. Additionally, in the study conducted by Wowk et al., the 
researchers demonstrated that simple linear polymers (in this case, polyglycerol and polyvinyl 
alcohol) could inhibit bacterial ice nucleation, specifically the ice nucleating activity of 
Pseudomonas syringae proteins. Polyglycerol was associated with higher potency and 
specificity, but the combined use of polyglycerol with polyvinyl alcohol resulted in more 
effectiveness than the independent use of each agent.120 
For the present research project, specificity is a fundamental prerequisite. In view of this, the 
dynamism and flexibility associated with linear polymers means that they are not suitable (see 
Figure 20a). Polyvalent effects underpin the interaction between linear polymers and proteins, 
which means that a directly proportional relationship exists between the number of charges 
present and the strength of the bond. Hence, size specificity is not a feature, and a linear 
polymer can dynamically alter its morphological and structural features to improve binding. 
Resultantly, interactions between linear polymers and proteins are designated as “non-
specific”.121 
 





Hyperbranched polymers and dendritic polymers, both of which are presented in Figure 20, 
were also considered in this research. Dendritic polymers are distinct when compared to 
conventionally branched polymers, specifically with respect to the branching possibilities at 
every monomer repeat unit. Hence, vast numbers of functionalized terminal groups exist in this 
structural arrangement. Owing to the fact that protein surfaces are highly charged in certain 
places, dendritic polymers were considered a promising possibility. 
Hyperbranched polymers are characterised by irregular branching architectures, which is the 
main feature that differentiates them from dendrimers. As a result of this irregularity, their 
flexibility is considerable, and – as was determined in the present study – potentially overly 
flexible. As noted previously, a high level of flexibility typically corresponds to a lower level 
of specificity, which is relevant because specificity is the principal focal point of this research 
project. In contrast, dendrimers are marked by the regularity of their branching architectures, 
their symmetric nature, and their property of being monodisperse. When considered in relation 
to hyperbranched polymers and linear polymers, dendrimers display a high level of molecular 
uniformity and an aspect of rigidity. Hence, it is possible to quantify their maximum 
addressable area as the square of their diameter. The functionalisation of a dendrimer’s outer 
surface is also a straightforward task, which lends itself to the mechanism of protein-protein 
binding, in which the matching of size, shape, terminal functionality, and the location of this 
functionality is critical. Hence, dendrimers hold considerable promise as potential large 
molecule inhibitors for protein-protein binding. 
The research group coordinated by Twyman reported on a size effect associated with 
dendrimers, which can be leveraged to formulate a size-selective binding mechanism for 
inhibiting protein-protein interactions. In other words, the optimal dendrimer for binding to a 




to the protein’s interfacial area. In the event that a large ligand interacts with an enzyme’s active 
site, it becomes blocked, thus undermining the enzyme’s function. Hence, the dendrimer that 
can bind most effectively is simultaneously the strongest inhibitor.35 The utilised dendrimers 
were PAMAM dendrimers, which are presented in Figure 21. The figure also shows the 




Figure 21: PAMAM dendrimers and addressable areas 
 
Ronald’s dendrimer-supported dynamic combinatorial chemistry (DCC), which is marked by 
high support loadings, homogenous purification, routine intermediate characterisation, and 
solution phase chemistry, relies on the use of dendrimers in the form of soluble supports. The 
results indicate that it is possible to generate effective combinatorial libraries using DCC. 




combinatorial libraries (DCLs) have significant potential for the advancement and 
interrogation of chemical complexity.36 
 
1.6 Dynamic Combinatorial Libraries 
 
Dynamic combinatorial libraries (DCLs) are aggregations of molecules that are in continuous, 
reversible equilibrium. Through the use of interactions, whether covalent or non-covalent, 
molecules of this kind can self-assemble into complexes that are thermodynamically 
controllable.37 The structural arrangement of the DCL is determined by the relative stability of 
each constituent, which is itself informed by exposure to external templates or factors (e.g., a 
protein). An illustration of DCLs is given in Figure 22. 
 
 
Figure 22: Dynamic combinatorial libraries (DCLs) . Image reprinted with permission from 





It is possible to combine a template molecule with the reaction, on the basis of the utilisation 
of DCLs, thereby driving it to the product that displays the most potent level of affinity for the 
template (informed by non-covalent effects and size). Consequently, the ideal dendrimer-chain 
complexes can be targeted for using proteins as template molecules to identify the 
configuration with the highest binding affinity. In view of this, the process of identifying new 
drugs, which has historically been time-intensive, can be made more efficient through the 
development of DCLs.39 Although the level of control associated with this method is 
acceptable, it is quite rigid for library generation because every structure must be designed and 
produced independently. Nevertheless, in the event that dynamic characteristics can be 
included in the generation procedure, it is possible to imagine a novel aspect of the 
combinatorial procedure. In such situations, the library becomes flexible and, moreover, can 
adjust autonomously based on the target macromolecule at a particular time in a particular 
environment. Furthermore, owing to the reversible processes of supramolecular and molecular 




































2.0 Aims and Objectives 
A helpful strategic approach for the inhibition of disease-related protein-protein complexes 
involves the development of macro-ligands with the capacity to interact with the expansive 
binding surfaces of proteins. Despite the fact that dendrimers have been successful, they do not 
bind in a selective manner. 
Previous studies have demonstrated that carboxylate dendrimers can bind to proteins with 
positively charged interfacial areas. The results of these studies indicate that it is possible to 
achieve selective binding by matching the size (or maximum addressable area) of the dendrimer 
to the protein’s interfacial area.15 Improved binding can be achieved by adding various amino 
acids to the dendrimers. Binding studies have also revealed that a tyrosine dendrimer binds 
most effectively to α-chymotrypsin, with an affinity that is 30% higher than a non-
functionalized dendrimer of compatible size and charge (Figure 23).  
Although the studies using mono-functionalized dendrimers exhibited improved binding, the 
approach was not appropriate for the synthesis of dendrimers with a range of different terminal 
groups. That is to say, it is not possible to regulate the three-dimensional position of every 
group in relation to the others. In the present study, the focal point of investigation was the use 





Figure 23: Covalently functionalized dendrimers as selective protein ligands.    
 
All in all, the experiments attested to the critical role played by functionality and size in the 
process of creating macromolecular ligands for selective protein binding. Despite the success 
of the results, and although they provide an unambiguous proof of concept, covalent chemistry 
is time-intensive, particularly in terms of the need to incorporate core functionality and specific 
terminal groups. Additionally, design or synthesis errors are complex to correct, the implication 
being that, in the event that they take place, it is necessary to synthesise the dendrimer ligand 
once again. Moreover, while including a single/specific functional group on several occasions 
to the dendrimer surface (i.e., polyvalency) is quite straightforward, it is a highly complex affair 
to position moieties of this kind with a geometric level of accuracy in a way that is relative to 
one another. It is a yet more complicated task to include a varying number of functional groups 
to produce multivalency with control in terms of their relative positions. Needless to say, design 
accuracy of this kind is a fundamental requirement for the covalent synthesis of any 




This study aims to develop a proof of concept methodology for acquiring selective 
macromolecular ligands for specific proteins. The aim is to establish a system in which the 
protein can select its optimal ligand from an expansive set of functionalized macromolecular 
ligands. Thus, this study attempts to establish a non-covalent methodology for assembling 
targeting groups both around and inside a dendrimer framework. Controlling the relative 
positions of targeting groups relies on the use of a target protein (i.e., as a template), thus 
guiding the formation of an optimised macromolecular protein ligand. 
 
 
Figure 24: Multivalent non-covalent method using a dynamic approach towards selectivity. 
On combining all constituents, self-selection of the optimised macro-ligand will occur.  
 
We propose a novel non-covalent methodology based on the design shown in Figure 24. The 
first aim of this project was to establish parameters that would maximise the encapsulation of 
the linear chain. This would include hydrophobicity and the effect of any additional binding 
(e.g. hydrogen bonds, as illustrated in Figure 25). Another aim was to investigate how a linear 
chain functionalized with different amino acids could moderate binding. Additionally, we 




use of functionalized linear chains on binding, it will also be necessary to conduct various 
control experiments to determine what effect the dendrimer and non-encapsulated linear will 
have on binding.  
 
 
Figure 25: Proposed linear chains that including hydrophobicity and additional hydrogen 
bonds required to maximize encapsulation within the dendrimer 
 
Another aim is to develop a protein binding system containing an additional molecule that can 
be used as a probe or sensor. This probe/sensor would be incorporated non-covalently, thereby 
producing a molecular design that can be modified conveniently for specific proteins by 
changing the linear chains and/or the probe/sensor. To be specific, this study pursues a novel 
paradigm that will utilise the modularised, non-covalent self-assembly of sensing and binding 




within the dendrimer, the binding units are characterised by their mobility. Hence, after adding 
a protein to the solution, the binding units change their position to heighten (cooperative) 
interactions with respect to the protein’s binding surface. This process is protein-controlled 
because it regulates the formation of its own optimised macromolecular ligand by seeking the 
lowest energy system (protein/dendrimer complex). This aspect is the same as the one 
described in the introductory chapter. However, by incorporating the sensor units and binding 
units in the assembly programme, binding may also be identified and, moreover, measured. 
For this part of the research project, the aim is to develop a non-covalent approach by which 
targeting and sensing units can be assembled around and within a dendrimer framework. 
 
Figure 26: Proposed self-assembled protein binding complex 1 and its binding to a target 
protein. A neutral/non-binding dendrimer acts as a scaffold to support and encapsulate the 
binding and sensing units. The use of non-covalent chemistry allows the targeting groups to 

























3.1 INTRODUCTION AND AIMS 
 
The complexes formed when proteins interact with each other or other biological 
macromolecules play essential roles in all biological processes.1 Illness is typically the natural 
result of conditions that lead to protein mutations, or uncontrolled or unwanted interactions.2 
Notable illnesses include neurodegenerative diseases such as Alzheimer’s and Huntington’s 
disease.3 Protein-protein interactions are also involved in viral and bacterial infections. For 
example, binding between proteins on the surface of bacteria and cells can facilitate the 
internalization of the bacteria within the host cell.4 Using a similar mechanism, it has been 
demonstrated that viral proteins can bind to host proteins, resulting in internalization and 
infection.5 As such, understanding how to modulate or inhibit protein-protein interactions is an 





Figure 27: Protein inhibition 
Complementary functionalities that are located at specific sites on large interacting surfaces, 
which can range from 500 A2 to 5,000 A2, allow one protein to recognize another, and the main 
element is referred to as the interfacial area.6 Hence, a difficulty that must be overcome in 




large to interact with a majority of a protein’s interfacial area, and ideally all of it.7 In addition 
to size, a range of non-covalent interactions are relevant to note in regards to the selectivity of 
an inhibitor. These non-covalent interactions include charge/charge, aromatic/π−π interactions, 
hydrogen bonding, and hydrophobic interactions.8 Research studies that have examined 
protein-protein interactions have reported on certain amino acids that contribute over 2 
kcal/mol to the binding energy in a consistent way, all the while appearing at the interfacial 
surface with a frequency exceeding 10%.9 Amino acids of this kind have the capability to 
engage in several interactions, and they include tyrosine (13%), arginine (14%), and tryptophan 
(21%). Hence, critical design elements to consider with respect to the acquisition of selective 
ligands for protein binding include functionality, charge, size, and multi/polyvalency. Given 
these requirements, it is not surprising that macromolecular ligands are associated with 
considerable promise with regards to protein binding. Examples include calixarene and 
porphyrin scaffolds,10,11 nanomaterials,12 and linear polymers.13,14  
Functionalized calixarene and porphyrin scaffolds, supporting diverse amino acids, were 
traditionally used in the literature, which had a high level of affinity for a range of groups in 
binding to certain proteins.14 Gilles et al. published the first study in which functionalized linear 
copolymers were used to bind enzymes with enhanced selectivity, which relied on the 
screening of co-monomers with varying types of amino acids.51 The researchers established a 
library of inhibitors for binding to several serine proteases, and the functionalized co-
monomers were used to inform selectivity. The co-monomer-amino residue interaction 
occurred on the surface of the protease and also inside the active site, as shown in Figure 23. 
Figure 23b indicates the collaboration among functionalized groups. Noteworthily, 
biphosphate co-monomers were identified as binding to the elastase surface, while an anchor 
monomer was found to direct an alanine terminal group to enter the active site and fill the 






Figure 23: Illustration of interaction between enzyme-targeting co-polymers and (A) serine 
protease, and (B) elastase 
 
Proteins are implicated in numerous biological processes, and the binding of a functionalized 
linear copolymer to a protein relies on the existence of complementarity between each partner’s 
functional groups. In view of this, the aim is to establish a linear chain polymer of key 
functionality that can interact in a cooperative manner with a positively charged protein. In this 
case, α-chymotrypsin is used. Additionally, the significance of a protein’s charged regions 
cannot be overlooked. As a case in point, interactions can take place between positively 
charged ligands and negatively charged porcine pepsin,52 or between negatively charged 
ligands and the positively charged serine protease hot spot. Hence, in the case of functional 
group interactions and targeting charge, both are consequential variables. 
The extreme dynamism and flexibility of linear polymers is well-documented in the literature. 




Given that linear polymers have the potential to improve binding by changing their shape in a 
flexible manner, size specificity is not a feature. As such, a directly proportional relationship 
exists between binding strength and the amount of charges. In view of this, interactions 
between linear polymers and proteins are regarded as lacking specificity.53 Hence, this study 
determined that the employment of a rigid polymer would be viable as a scaffold for a 
functionalized linear chain, thereby heightening the binding affinity. 
Dissimilar to hyperbranched polymers, the rapid and convenient synthesis of which is a core 
characteristic, dendrimers are complex to synthesise.54 Therefore, any venture to synthesise 
dendrimers should be undertaken if and only if the properties of these molecules, and no other, 
would be satisfactory for a particular application. One of the qualities of dendrimers that makes 
them especially valuable in replicating protein binding partners is their spherical nature, which 
stems from the regular nature of their branches. Additionally, the rigid nature of a dendrimer’s 
architecture means that binding is maximised only if the location of the complimentary 
functional groups on the protein and the dendrimer correspond to one another. Consequently, 
dendrimer binding is more cost-effective when compared to linear polymer binding in an 
entropic way, which is advantageous for molecule design initiatives because it promotes the 
enhancement of binding energy. Furthermore, dendrimers are distinct when compared to 
polymers due to the dense nature of their surface groups.55 Generational synthesis offers 
quantised sizes, thereby promoting the formation of molecules that can bind selectively and 
specifically to target protein binding sties. 
In view of the above considerations, dendrimers were chosen for this study’s synthetic 
inhibitors. If the study is successful, it will be possible to design and produce macromolecules 
that can inhibit specific enzymes, bind and purify proteins, and open up new routes for drug 




research project could solve problems relating to drug specificity and physical properties, 
particularly in view of the way they can contain and transport small active molecules to target 
proteins.41    
 
3.2 Results and Discussion 
 
Therefore our initial aim to synthesis of various PAMAM dendrimers with discrete sizes was 
conducted to obtain the optimal dendrimer for binding a target protein (e.g., α-chymotrypsin), 
and also to create cavities for the encapsulation of functionalized linear chains. The divergent 
approach was used for the synthesis of dendrimers from generation 0.5 (1) to 3.5 (7) with 4 and 
32 ester terminal groups, respectively.  
 
3.3 Synthesis of PAMAM dendrimers  
 
The purpose of the preliminary phase of the process is to determine whether dendrimer 
PAMAM can improve the solubility of linear chains. As mentioned before, PAMAM 
dendrimers are marked by their branched, well-defined structure and can be classified as 
monodispersed macromolecules. The literature indicates that they can effectively encapsulate 
small organic molecules within a hydrophobic interior or surface of dendrimers (interaction 
between dendrimers and drugs).18-19 It is possible to change the terminal functional groups to 
achieve solubility in a particular solvent. The link between the linear chains and the dendrimer 
may occur based on non-covalent interactions (linear chains encapsulated inside the dendrimer) 
Therefore, the synthesis of PAMAM dendrimer started with the G0.5 dendrimer (1) was 
synthesized by reacting ethylene diamine (EDA) with methyl acrylate at room temperature, as 




unsaturated carbonyl group of methyl acrylate using the amine on ethylenediamine (EDA). 
EDA has two amine groups, each of which has two hydrogens. Therefore, EDA can react with 
four molecules of methyl acrylate to give the G 0.5 dendrimer (1). Methyl acrylate was used in 
slight excess to ensure complete nucleophilic addition. The excess solvent and methyl acrylate 
was removed using a rotary evaporator. 
 
Scheme 2: Mechanism for the synthesis of the half generation dendrimers 
 






Confirmation that the reaction had completed came from 1H NMR analysis, as shown in Figure 
28. The methoxy peak was visible as a singlet at 3.68 ppm, and a second singlet at 2.53 ppm, 
which integrated to 4H, was assigned to the core EDA protons. The excess methyl acrylate had 
been completely removed, as no signals were visible   5-6 ppm. 13C NMR and FTIR spectra 
showed an ester peak C=O at 172 ppm and 1735 cm-1. The mass spectrum supported the 
structure with a molecule ion at 405 (MH)+. 
The full-generation dendrimers were synthesized by the reacting half-generation dendrimers 
with an excess amount of EDA. The lone pair of electrons on EDA’s nitrogen atom reacted 
with the ester, resulting the electrophilic carbon resulted in the loss of methanol, as shown in 
Scheme 3.  
 
 
Scheme 3: Mechanism of G 0.5 (1) into G 1.0 (2) 
Excess EDA was used to ensure that  the reaction reached completion. Remaining EDA was 
removed with an azeotropic mixture (9:1 v:v) of toluene and methanol, which is an effective 
competitor for EDA hydrogen bonding and has a higher boiling point that EDA. 1H NMR was 




at 2.71 ppm (Figure 29) If any EDA remained during the next step, it reacted with methyl 
acrylate to generate G 0.5 dendrimer (1). This created an impurity that can not be removed. 
1H NMR spectra confirmed that a singlet peak at 2.71 ppm was no longer visible after washing 
with 2.0 L of an azeotropic solvent. These techniques were repeated to form G 3.5 (7) 
dendrimers. To confirm, the characterizations of half-dendrimers were summarized in Table 1. 
 
Figure 29: Comparison of 1H NMR spectra for G 3.0 after a series of washes with the 
azeotropic solvent.  
  
However, the ester dendrimer G3.5 (7) is not suitable for protein binding because esters rapidly 
hydrolyse to negatively charged carboxylic acids and the amine dendrimer are protonated. 
Therefore, as both are charged, neither are suitable for clinical and biological application.  For 
that reason, we selected neutral G3.5-OH as our scaffold for functionalized liner chains. 
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3.4 Synthesis of dendrimers with hydroxy terminal groups 
 
To provide of this novel methodology, as well as a demonstration of how non-covalent 
combinatorial chemistry can be employed to facilitate the functionalization of the dendrimer 
with targeting groups at the same time. The exact process would rely on the use of non-
functionalized dendrimers G3.5 PAMAM dendrimer (8149 Da) with OH terminal groups, on 
this will depends on the specific surface of the target protein of α-chymotrypsin. Noteworthy, 
these can be created without difficulty, and they can be acquired commercially. 
For the proposed design of our non-covalent unfactionalized dendrimer, the use a neutral 
dendrimer that cannot bind was also required. The dendrimer would need end groups that allow 
it to be water-soluble, and ethanolamine was selected as this would give dendrimers with OH 
end groups. The addition of ethanolamine was carried out using a process similar to that used 
for the full-generation dendrimers. The reaction and the mechanism of this conversion are 
shown in Scheme 4 . In this case, a base was required because the OH is not basic enough to 
deprotonate the charged intermediate.  
Our previous studies reported that ethanolamine and dimethyl sulfoxide (DMSO) were difficult 
to remove. Attempts to avoid and maintain a basic environment were carried out using an 
excess amount of ethanolamine and potassium carbonate, without DMSO. However, the 
product was not soluble in water, thereby suggesting that the hydroxy groups were only 








Scheme 4: Mechanism of ethanolamine group with potassium carbonate (B) to produce 
hydroxyl terminal groups 
 
To avoid the solubility problem, a minimum amount of DMSO (to solubilize dendrimer) was 
combined with the mixture. After purification, which was achieved by filtering under vacuum 
and trituration with acetone, the products were collected as a paste, allowed to settle before 
collection and then drying under vacuum. Crystals of potassium carbonate formed on the 
surface of the paste, and these were dissolved and removed by dissolution with small amounts 
of water. The product was then obtained using a second trituration with acetone. However, a 
singlet peak at 2.64 ppm and a triplet peak at 3.52 ppm, corresponding to DMSO and 
ethanolamine, respectively, were visible in the 1H NMR spectra of G 2.5-OH. Repeated 
trituration from water using acetone were carried out. The product was dried, and complete 
removal of impurities was confirmed in 1H NMR, as shown in Figure 31: 1H NMR spectra for 
G 2.5-OH. The same technique was used to build the G 1.5 and G 3.5-OH dendrimers (Figure 




























ion (MH) + 
G 1.5-OH    
(8) 
C62H120N18O20 1438 8     1438 
G 2.5-OH 
( 9) 
C142H272N42O44 3272 16     3272 
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3.5  Synthesis of linear chain 
 
As noted above, a key element of the process was the non-covalent incorporation of the 
targeting groups. In particular, the amino acids that can bind to the dendrimer’s interior using 
hydrogen and hydrophobic bonding interactions would be included at the end of a hydrophobic 
linear chain. It was possible to synthesize several of these functionalized linear chains and add 
them to a dendrimer to yield a functionalized system (Figure 33). 
 
Figure 33: Proposed linear chains that include hydrophobic and hydrogen bond interactions to 
help encapsulation with the dendrimer. 
 
This study aimed to exploit a series of macromolecules and develop a proof of principle 
methodology for obtaining selective ligands for specific proteins. The overall objective was to 
develop a system in which the protein can select its optimum ligand from a large pool of 




hydrophobic linear chains and the level of encapsulation within the dendrimer have been very 
poor. Therefore, our initial step was to find the simplest method to synthesize functionalized 
and hydrophobic linear chains, with each having a different number of hydrogen bonding sites, 
and to investigate which encapsulated optimally within the PAMAM dendrimer. Therefore, we 
would then be able to determine which chain was best, based on the of synthesis versus the 
ability to bind reasonably to the dendrimer. 
 
 Linear chains 
R= Various amino acid functional groups 
Number of hydrogen 



























3.5.1 Synthesis of the one amide H-bonding linear chain 
 
The first synthetic route involves applying a simple method that provides one hydrogen 
bonding site. This was based on a prior study that demonstrated how hydrophobic drug 
molecules could be encapsulated within dendrimers to enhance their solubility. Based on these 
findings, our first attempt was the synthetis of a hydrophobic chain that possessed just 1 H-
boning group.  The synthesis was between 1-tetradecylamine and tyrosine, to generate a Boc-
Tyrosine chain (1HB-LC-Boc-Tyr). 11  The reaction was a simple amide coupling using the 
carboxyl activating coupling agent EDC.HCl. To avoid unwanted coupling, selective 
protection of the tyrosines amine group was necessary. In this case, a tert-butyloxycarbonyl 
(Boc) protecting group was chosen. The Boc groups were removed using TFA and DCM. The 
synthetic route to 1HB-LC-Tyr is shown in Figure 35 1H NMR confirmed the attachment of 1-
tetradecylamine based on the aromatic doublets at 7.0 ppm and 6.71 ppm. The protons on the 
chain resonated as a broad peak at 1.31 ppm, which integrated for 24 protons. The Boc peak 
was detected as a singlet at 1.41 ppm. Mass spectrometry indicated a molecule ion at 499.6 
(MNa+), which confirmed the structure of Boc 1HB-LC-Boc.Tyr 11  
The deprotection of the Boc group was achieved using TFA in DCM.  It was necessary to use 
a relatively high concentration of TFA to ensure complete removal of the Boc group.  However, 
if insufficient deprotection takes place, it is clearly observable from the 1H NMR spectrum 
(Figure 34) 1H NMR confirmed the purity of the 1HB-LC-Tyr 12. In additiom, mass 





















3.5.2 Synthesis of the two amide H-bonding linear chains 
 
The experiment was continued to prepare with 2 hydrogen bonding of linear chain that can 
provide the additional binding within dendrimer. The planned synthetic route for two hydrogen 
bonding 14 is shown in Scheme 6.  The first step involved addition of a tert-butyloxycarbonyl 
(Boc) group to protect the amine group from unfavorable reactions. The Boc group was used 






The attachment of the Boc group, which integrates as 9 protons, was confirmed by 1H NMR 
analysis, where a sharp singlet was visible around 1.40 ppm. The successful addition of -
alanine was also confirmed by integrating the broad singlets at 2.61 ppm and 3.42 ppm, which 
are assigned as for CH2 protons. Mass spectrometry had a molecule ion at 188 (MH
+) and 212 
(MNa+), which confirmed the structure of Boc amide (12) 
 
  
Scheme 6: Planned synthetic route with two hydrogen bonding groups 
The next step was coupling of Boc-β-alanine with heptylamine, giving of Boc-heptylamine 13. 
This was carried out using EDC.HCl and DMAP in a 1:2 ratio and the addition of base of 3 
equivalent of basic triethylamine. Analysis by 1H NMR showed two doublets of doublet peaks 
between 7 and 8 ppm. The ES-MS spectrum had a signal at 123 (MH+), indicating the presence 
of DMAP in the product. Therefore, the crude product was dissolved in chloroform and 
rewashed with water and a concentrated sodium hydrogen carbonate solution to remove the 






indicating the washing was successful. White crystals were obtained and the yield was 55%. 
The 1H NMR spectrum had peaks at 3.28 ppm and 2.71 ppm eac integrating as two protons, 
and these were assigned as the CH2CO and CH2NH2, respectively. A triplet at 0.92 ppm was 
observed for the terminal methyl group and the integration of 8 protons at 1.30 ppm of CH2 for 
the remaining protons from heptylamine. The singlet at 1.45 ppm, which integrated as 9H, was 
assigned to the Boc group. The ES-MS spectrum showed a signal at 287 for the MH+ and 309 
(MNa+) ion, confirming that synthesis of the pure protected chain 13 had been achieved. A 
further step was carried out to remove Boc using trifluoroacetic acid (TFA). This was 
undertaken based on the mechanism given Scheme 7, which allowed the carbon dioxide 
byproduct to bubble away.  
  
Scheme 7: Mechanism of Boc deprotection 
 
The Boc group was successfully removed to give amine 14 with few impurities, as confirmed 






chain 14. TFA was removed by evaporation and solvent extraction, giving to the deprotected 
chain 14  in a yield 78 %. The pH of the solution was also monitored to ensure that no TFA 
remained, and multiple solvent extractions were carried out in order to remove TFA and all 
other impurities. An absence of the sharp singlet at 1.45 ppm for the Boc group in the 1H NMR 
indicated the successful removal of the Boc group (Figure 36). Mass spectrometry analysis 
confirmed the mass of amine 14 with a molecular ion at 187 (MH+). The next step involved 
addition of the amino acids. 
 
 










3.5.3  Synthesis of two linear chains with tyrosine and valine 
 
In a previous study, it was demonstrated that the functionalized dendrimer with tyrosine chain 
(3 hydrogen bonding) was associated with the greatest number of encapsulation/binding. In 
view of this, the same amino acids (i.e., tyrosine and valine) were chosen to examine the impact 
of different amino acids on binding, where these served as capping groups for the linear chain. 
Tyrosine was chosen because it plays a critical role in protein binding, while valine is 
documented as having a negligible impact on binding. Thus, when encapsulated into a 
dendrimer, our expectation was that the level of inhibition would be low.  
Tyrosine was added to the linear chain as previously described by amide coupling of Boc-Tyr-
OH to amine 14. Scheme 8 to give 2HB-LC -Tyr 22 and 2HB-LC -Val 24. Both reactions were 
carried out using the same procedure and characterizations, as mentioned before in Section 3.5. 







Scheme 8: Addition of tyrosine and valine to 2 hydrogen linear chain by an amide coupling 
and Boc deprotection step 
  
The confirmation of the addition of the tyrosine group for the synthesis of 2HB- Boc-tyrosine 
chain 15 was achieved after observing the peaks at 7.05 ppm and 6.72 ppm in the 1H NMR 
(corresponding to the aromatic protons of the tyrosine group) and the singlet peak at 1.4 ppm 
(corresponding to the Boc group). Additional mass spectrometry evidence confirmed the mass, 
where a molecular ion was observed at 450 (MH+). The Boc deprotection of tyrosine chain 21 
with TFA was undertaken as before, and 1H NMR confirmed that the singlet peak at 1.4 ppm 






TFA, 2HB-LC –Tyr 22 was placed under a vacuum for an extended for 5 days. The 1H NMR 
spectrum of 2HB-LC –Val 24 showed peaks at 5.28 ppm (N-H) and a peak for the stereogenic 
CH at 3.55 ppm. At the same time, a doublet 0.99 ppm and a septet at 2.26 ppm confirmed the 
presence of an iso-propyl group. The successful preparation of 2HB-LC Val 24 was confirmed 
from the mass spectrum which had molecular ion at 285 (MH) +. 
 
 3.5.2 Synthesis of the three amide H-bonding linear chains 
 
Having successfully synthesised the one and two hydrogen bonding chains, the next step was  
preparation of a linear chain that could provide three hydrogen bond interactions within the 
dendrimer. The synthesis of the chain began from a smaller alkyl amine, and the chain was 
built up by repeated addition of  -alanine 14 using the same method previously used for the 
other linear chains. 
The synthesis is similar to that used to prepare the two hydrogen bonding linear chain. In order 
to add the extra amide, and keep the chain length similar, the synthesis started with a shorter 
alkyl chain. As before, the same method was used for Boc protection of -alanine 14 to give 
amide 16. Conformation of Boc protection came from 1H NMR, where the broad singlets 
observed at 2.61 ppm and 3.42 ppm, assigned as the CH2 protons, and a singlet at 1.39 ppm for 
the Boc group. Mass spectrometry was undertaken which had a molecule ion at 188 (MH+) and 









Scheme 9: Synthetic route of the linear chains 
 
In the next reaction, propylamine was combined with chain 16 to give the diamide 17, as shown 
in Scheme 8. The signal for the Boc group was observed at 1.45 ppm, which integrated as 9H,. 
Additionally, the synthesis of the pure protected chain 17 was indicated by the fact that the ES-
MS spectrum displayed a molecular ion at 231 for the MH+ ion. Following the successful 
synthesis of the protected chain 17, the Boc group needed to be removed. TFA removal took 
place  as previously described  and the deprotected chain 18 was obtained in a yield of 82%. 
Monitoring of the solution’s pH was used to ensure removal of TFA. A lack of the Boc signal 
at 1.45 ppm in the 1H NMR analysis demonstrated Boc removal. In addition, mass spectrum 






combine a second Boc--alanine group with the chain. In this case, DCM was not an effective 
solvent because the deprotected compound was more polar, and amide 18 was insoluble. 
Therefore, DCM was replaced with tetrahydrofuran (THF). The 1H NMR spectrum revealed 
peaks that were consistent with the product, namely a sharp singlet peak for the Boc group at 
1.42 ppm and the terminal methyl group as a triplet at 0.93 ppm. Mass spectrometry supported 
the presence of the mass of amide 19 with a molecular ion at 302 (MH) +. The deprotection of 
the compound was facilitated to generate amine 20.  
 
At this stage we had the linear chain and now needed to add the tyrosine and valine terminal 
groups.  The synthesis of the tyrosine and valine chains is shown in Figure 37 and uses the 
same coupling/deprotection steps previously described ( see section 3.5.3). This resulted in 
3HB-LC -Tyr 26 and 3HB-LC-Val 28. The successful synthesis of the protected 3 hydrogen 
bond Boc-tyrosine chain 25 was confirmed by 1HNMR, where by peaks were observed at 7.05 
ppm and 6.71 ppm, corresponding to the aromatic protons of the tyrosine group and a singlet 
at 1.39 ppm, corresponding to the Boc group. This was supported by mass spectrometry, which 
indicated aa molecular ion at 487.5 (MNa+). Boc deprotection using TFA was successful, as 
demonstrated by 1H NMR and mass spectrometry.  The singlet at 1.4 ppm from the Boc group 
could no longer be observed in the NMR spectrum. The mass spectrum displayed a molecular 
ion at 299 corresponding to the molecular ion (MH+) along with a peak at 323 (MNa+). This 







Figure 37: Synthesis route of three amide with valine and tyrosine 
 
In conclusion, the 3 hydrogen bonding system was the hardest to synthesize,   however, it does 
have the potential for better encapsulation within the dendrimer, and therefore better potential 
for protein binding. The next step will be to test how well the linear chains produced can be 








3.6 Encapsulation of functionalized linear chain 
 
As mentioned before, the encapsulation of hydrophobic molecules has been identified as a 
method for enhancing the solubility of drugs. In order to organize shape dendrimer as a scaffold 
for the functionalized linear chain, the selected dendrimer must be water-soluble. This ensures 
that the protein and the assembled ligand are in the same aqueous phase. In addition, the 
dendrimer’s terminal groups must be neutral and inert. This is vitally important because the 
dendrimer must not react, bind, or interact with the protein’s binding surface in the absence of 
any encapsulated functionality. Additionally, the dendrimer must be sufficiently large to 
address the full size of the target protein’s interfacial area, whilst also ensuring that the 
incorporation of the binding is not prevented or limited by a dense shell or dense packed 
structure.19,20 As such, the neutral G 3.5 PAMAM dendrimer 10, with 32 terminal OH groups 
22 and a maximum addressable area of 1200 A2 was selected as the scaffold unit.23,15  
 









The next step involved the targeting or binding units that needed to be 
encapsulated/incorporated within the dendrimer’s interior. A cooperative combination of 
hydrophobic, electrostatic, and H-bonding interactions was chosen to drive encapsulation. To 
achieve this, a series of hydrophobic oligomeric amide chains, terminated with an amino acid 
(the binding functionality), were selected. For this proof of principle work, a tyrosine 
terminated chain 22 was selected as the binding/recognition motif, and a valine terminated 
chain 24 was selected as a control. These amino acids are known to contribute significantly 
well or extremely poorly, respectively, to protein-protein interactions.9  
Encapsulation of the linear chains within the G 3.5-OH dendrimer 10 was achieved using a 
procedure similar to that used to solubilize and encapsulate hydrophobic drugs within water-
soluble PAMAM dendrimers.25 For the linear chains, 10 equivalents of  each linear chains were 
added to methanolic solutions of dendrimer 10. The methanol was removed and a known 
volume of buffer (0.01M PBS, pH 7.4) was added, to give a final dendrimer concentration of 
1×10-6 M. The proportion of encapsulated chains within the dendrimer was calculated, as 
shown in Table 4. Each absorbance was divided by the extinction coefficient (ε) of the linear 
chains. To measure the loading encapsulation, the concentration of the dendrimer was divided 
by the concentration of the functionalized chain.  The first experiment was involved 1 HB-LC-
Tyr that showed a poor loading with 1 or 2 chain (s) per dendrimer. 
Therefore, the experiment was continued with 2 hydrogen bonding sites (2HB-LC). Beer-
Lambert analysis confirmed that all 10 linear chains had been encapsulated, giving a final 






(Table 5). This is greater than the solubility of either linear chain without the dendrimer (1.16 
×10-5 M for 2HB-LC-Tyr 22 and 4.24×10-5 M 2HB-LC-Val 24).  
 
 



















Tyr 22 0.1088 n/a 9326 1.16E-05 n/a 
Complex 0.2332 2.50E-06 9326 2.50E-05 5.34E+00 
Table 4: UV absorbance before and after encapsulation of G 3.5-OH with 2HB-LC-Tyr 22 
 
























LC-Val 24  0.1014 n/a 2389.9 4.24E-05 n/a 
Complex 0.1621 2.50E-06 2389.9 6.78E-05 5.08 
 
Table 5: UV absorbance before and after encapsulation of G 3.5-OH with 2HB-LC-Val 24 
Furthermore, a 10-nm bathochromic shift was observed in λmax when either 2HB-LC-Tyr 22 or 
2HB-LC-Val 24 were encapsulated within the dendrimer. This shift is consistent with a change 
in environment, as the water solvating the linear chains is replaced by the dendrimer’s interior 
groups. Overall, the solubility and spectroscopic data confirm that all 10 linear chains were 
encapsulated within the dendrimer. It is assumed that the driving force for complexation was a 
cooperative process involving hydrophobic and H-bonding interactions (Figure 40). The 
methodology is similar to that used by Meijer to construct dendrimer complexes that can 







Figure 40: Schematic showing a segment of the G 3.5-OH dendrimer 10 and possible H-
bonding motif to the linear chain, 2HB-LC-Tyr 22 
 
The same experiment was repeated for 3HB-LC-Tyr 26 and 3HB-LC-Val 28, showing that, 
when the bathochromic shifted from 270 nm to 275 nm, this confirmed encapsulation within 
the dendrimer with six of chains encapsulated within the dendrimer through 
supramolecular/non-covalent interactions. It also confirmed that the neutral dendrimer’s ability 
to operate as a scaffold for the linear chain. Having established and quantified the encapsulation 
of the various components, the next step involved a series of binding experiments to test 










In conclusion, the synthesis of all dendrimers and linear chains proved to be successful. The 
experiments attested to the critical role played by functionality and size in the process of 
creating macromolecular ligands for selective protein binding. This study focuses on the use of 
OH-ended neutral dendrimers for encapsulation, which were synthesised from ester-terminated 
dendrimers, followed by addition of ethanolamine to provide terminal OH groups.  To identify 
the dendrimer’s maximum loading capacity, a 10 fold excess of linear chains was used with a 
constant dendrimer concentration of 1x10-5 M. The level of encapsulation was estimated using 
UV spectroscopy, which showed that more of the 3 H-bonding chains could be encapsulated 
relative to the other chains.  Specifically, all 10 linear chains could be encapsulated for the 3 
H-bonding system, versus 5-6 for the 2 H-bonding system.  Only 1-2 chains could be 
encapsulated for the 1 H-bonding linear chain. The methodology is similar to that used by 
Meijer to construct dendrimer complexes that can aggregate on dilution.. Therefore future 
studies would concentrate on the 3 and 3 H-bonding systems to see which would bind better to 
the target protein.  Overall we wanted to see which would perform best with respect to a 
compromise between protein binding and ease of synthesis. Therefore, our next aim was to test 



























4.0 Introduction and Aim 
Macromolecular scaffolds are associated with a range of structural characteristics that lend 
themselves effectively to protein surface binding. In the presence of several surface contacts 
between the polymer and the protein, the efficiency of the binding can be increased.43, 44 The 
flexible nature of polymers, as well as their status as large molecules, provides a sufficiently 
sizeable area for contacting with a target protein, which generates numerous applications in the 
field of identifying protein external surfaces. 
Protein surface targeting has multiple practical uses, one of the main ones being enzyme 
inhibition. The protease enzyme family includes many proteins that have the capability to 
hydrolyse amides and esters. Additionally, an expansive group of natural protein inhibitors has 
been identified as binding to the active sites and surface regions of elastase, α-chymotrypsin, 
trypsin, and other serine proteases.45 Most protein inhibitors that have been identified and 
characterised in the literature are oriented towards α-chymotrypsin. α-Chymotrypsin was used 
as this study’s target for testing the inhibition potency of a synthetic protein receptor. This 
study sought to synthesise inhibitors for targeting the active sites, but the active sites are 
marked by considerable similarity. Hence, it is a complex affair to find a specific inhibitor that 
corresponds to every protease enzyme. In view of this, creating inhibitors for surface binding 
represents a new strategy. Structurally speaking, α-chymotrypsin is a ring of positively charged 
residues organised around an active pocket and scattered surface hot spots.12  
It is possible to target these hot spots as part of a strategy to formulate a surface-based inhibitor. 
α-chymotrypsin leverages its cationic residues to connect with anionic synthetic inhibitors and 






and – more recently – graphene oxide.49 Nevertheless, due to the additional non-covalent 
interactions stemming from amino acid functionality, protein binding is marked by specificity 
and high affinity. This is the case even in spite of the main interaction’s electrostatic nature. A 
research project that sought to examine the effect of amino acid preferences and functionality 
on interfacial areas and hot spots revealed that arginine, tyrosine, and tryptophan – if present – 
were often identified with hot spots.12 Although these amino acids are relatively rare in protein 
structures,50 they are largely responsible for non-covalent interactions.     
Despite the fact that it was not possible to detect binding with only the neutral dendrimer, the 
assessment of binding will occur when functionalized chains are included. This will suggest 
that control of the three-dimensional arrangement of terminal groups to lock on the template 
of protein of α-chymotrypsin. Therefore, , an enzyme inhibition assay was used to evaluate the 
functionalized dendrimer’s protein binding  
 
4.1 Assessment of Protein Binding Using an Enzyme Inhibition Assay 
As mentioned before, the key assumption underpinning this process was that access of the 
substrate to the active site could be prevented or inhibited by binding to the enzyme surface. 
The relevance of this is strong in relation to α-chymotrypsin, where the active site entrance is 







Figure 41: The surface of α-chymotrypsin (Chy). Image reprinted with permission from [De, 
M., Chou, S. S. and Dravid, V. P. J. Am. Chem. Soc. 133, 17524–17527 (2011)]31 
  
In a prior study, our group leveraged this principle in order to demonstrate that a size-based 
relationship existed between protein binding and dendrimers.17, 34 Additionally, in the study 
conducted by De and Dravid, the researchers drew on the same assumption to show that 
unfunctionalized graphene oxide, which is negatively charged, has the capability to interact in 
an electrostatic way with α-chymotrypsin.31 
Initial rates for every species were identified at a range of substrate and inhibitor concentrations 
(see equation 1) for the purpose of generating more comprehensive kinetic and inhibition data, 
and also to identify the mode of inhibition. In turn, the initial rates were plotted against the 
inverse of substrate concentration using GraphPad,36 and the plots for every experiment were 

















where Km is the Michaelis-Menten constant (concerned with the binding effectiveness of the 
substrate to the enzyme), Vmax is the maximum enzyme velocity upon saturation with the 
substrate, and Ki denotes the inhibition constant (concentration must inhibit 50%). It is also 
noteworthy that the parameter α can be generated from this model, and it provides valuable 
information about the inhibition mechanism  as shown in Figure 41.37  
The objective of this study is to increase the dissociation constant (KI) of the enzyme-inhibitor 
complex for the purpose of desensitising the enzyme to an inhibitor (Scheme 10). The 
equilibrium expression for enzyme, inhibitor and the EI complex re-arranges to the form 
[E]/[EI] = [KI][I]. Therefore, as the size of KI increases, the quantity of [E] available for 
catalysis is also larger. 
 
 








To arrive at the Michaelis constant Km, Vmax (maximum velocity) is halved. If Km changes from 
100 μM (uninhibited) to 400 μM (inhibited), then α is 4. In other words, stronger enzyme-
inhibitor binding is indicated by higher Km and α values. A mixed-model inhibition plot shows 
how the the initial velocity of the enzyme varies with the concentration of substrate (Figure 
42a). Transforming these data to a Lineweaver-Burk or double reciprocal plot, shows that the 
reciprocal of initial velocity varies according to the reciprocal of the concentration of substrate 
(Figure 42(b). 
 
Based on the value of Vmax, Lineweaver-Burk plots were also used to establish the mode of 
inhibition. Competitive inhibition is indicated by an unchanged Vmax and the same y-intercept 
(with or without the inhibitor) (Figure 43). In that instance, the inhibitor and substrate compete 
for the same active site. Where the inhibitor binds before substrate, the reaction rate is reduced 
leading to an increase in Km. As raised previously, higher Km values are indicative of weak 
binding interactions between the enzyme and substrate, and the converse where Km is low. The 
Vmax value differs with uncompetitive and non-competitive inhibitors. There is no effect upon 








(a) Mixed-model inhibition           (b) Transformed into Lineweaver-Burk 
Figure 42: Mixed inhibition data transformed into double reciprocal Lineweaver-Burk 
analysis using GraphPad Prism 7.03 
 
 












Figure 44: The type of inhibitor present can be explained by its effect on the degree of 
inhibition. a) When α ˃ 1, binding of the substrate to the enzyme is prevented by the inhibitor, 
this condition is referred to as competitive inhibition; b) when α =1 is the condition in which 
the substrate binding to the enzyme is unaffected by the inhibitor called non-competitive 
inhibition; c) When α ˂ 1, the inhibitor binds to the enzyme-substrate (ES) complex preventing 







In the event that the value of α is greater than 1.0, the substrate and the inhibitor compete for 
the enzyme in a process known as competitive inhibition. Additionally, the size of α is 
indicative of the relative binding affinity for the dendrimer substrate inhibitors. Contrastingly, 
when the value of α is less than 1.0, a non-productive ternary complex is formed after the 
inhibitor’s binding to the enzyme/substrate complex. This process is referred to as 
uncompetitive inhibition. Lastly, when the value of α is equivalent to 1.0, non-competitive 
inhibition takes place, where the substrate and inhibitor binding to the enzyme are not 
dependent on one another, but the enzyme/substrate complex is not productive. 
 
Figure 45: The degree of inhibition (α) dependent/related parameters with the Vmax, Km, [I] and 
Ki. 
 
 Nevertheless, a range of interactions other than electrostatics are involved in protein binding. 
The active site entrance of α-chymotrypsin also incorporates functionality that has the capacity 







4.2 Inhibition using 2 hydrogen bonding chain 
The intention of this part of the study is to determine how important and strong the polyvalent 
interactions from the amino acids of 2 hydrogen bonding  are when binding proteins. If this 
methodology is valid, then the dendrimers functionalized with amino acids known to be 
involved in protein-protein binding, should bind well to the surface of α-chymotrypsin and 
inhibit its function. On the other hand, a dendrimer functionalized with valine, which is not 
associated with protein binding, would result in weaker binding and less inhibition. This is the 
same hypothesis used in the previous work described by Bogan and Twyman. 12,67   If 
polyvalent interactions are not observed or if the orientation of the chains is not compatible 
with binding, then there will be no change in binding. In that instance, the kinetic and inhibition 
data would be the same as that measured in the G3.5-OH 10 control reaction/experiment. 
 








Scheme 11: Enzyme-mediated reaction for assessing relative binding to α-chymotrypsin 
In view of this, adding complimentary functionality to the dendrimer’s surface was expected 
to enhance selectivity. For the purpose of evaluating binding,  the inhibition of α-chymotrypsin 
to conduct the hydrolysis of the enzyme substrate N-benzoyl tyrosine p-nitroanilide (BTNA) 
was studied.Following hydrolysis, BTNA produces an aromatic species 30 that is characterized 
by a yellow hue, and which can be employed to follow the hydrolysis over time. It is then 
possible to determine the initial rates based on the plots of concentration against time for the 
nitro aniline product 30.  This will allow us to study binding by plotting initial rates at various 
substrate’s concentration to get the kinetic parameters (Such as Ki, α etc). At the outset, BTNA 
as a substrate was used to generate a baseline/control for α-chymotrypsin activity without the 
presence of inhibitor. This is in order to determine the conditions of the experiments and to 
verify that there was no interaction or reaction between BTNA . Thus, all inhibition was a 
direct consequence of interaction between the inhibitor and the protein. . 
For the control reaction, 2.0 µM BTNA and 0.4 µM α-chymotrypsin in 0.1 M phosphate buffer 
was employed for the reaction, and 0.4 µM α-chymotrypsin pre-incubated with 0.4 µM of the 






G3.5-OH-Val, and G3.5-OH-Tyr. In every experiment, the hydrolysis product’s 30 
concentration was plotted versus time, as shown in Figure 47. GraphPad was used to identify 
initial velocities,36 and the data were fit with linear regression. This permitted an assessment 
of whether or not it was possible for the neutral dendrimer to bind . In turn, the reaction was 
undertaken again with G3.5-OH, where the final concentration was the same as the enzyme 
(i.e., 0.4 µM). In line with expectations, the profile remained unchanged, thereby verifying that 
G3.5-OH does not inhibit the reaction or bind to the protein. This can be accounted for by 
referencing the fact that the dendrimer lacks groups that can interact with the other groups 
present on the protein or the charged surface .  
20% of the enzyme’s activity in relation to the control was inhibited by 2HB-Tyr (inhibited 
reaction). The results given in Figure 45 the effectiveness of the neutral dendrimer as an 
inhibitor upon functionalization with tyrosine. Contrastingly, valine-functionalized dendrimers 
were associated with the lowest level of inhibition, and thus the weakest binding. Valine is 
frequently found in protein structures, but there is limited availability of valine at the 
binding/interfacial areas. As a consequence, binding after the addition of functionalized chains 











































Figure 47: Rate plots employed to identify initial velocities (V) for the hydrolysis of 2.0 µM 
BTNA with 0.4 µM chymotrypsin in the absence and presence of 0.4 µM dendrimer inhibitors 
 
Inhibitor No inhibitor G3.5-OH/non 
functionalized 
2HB-LC-Val  2HB-LC-Tyr 
Initial rate (nMs-1) 0.716 0.718 0.670 0.575 
Table 6: Provides an overview of the plots for the G3.5-OH-Tyr. 
BTNA concentration 
(µM) 
2.0 4.0 6.0 8.0 
No Inhibitor 






































































Table 7: Initial rates identified with different inhibitor and substrate concentrations, with 
experiments undertaken using 0.4 µM chymotrypsin 
 



























































Figure 48: (Top) Plot of BTNA concentration against initial rate at several functionalized 
G3.5-OH concentrations. Values for α, Ki, Km, and Vmax were generated by fitting data to 
equation 1 (fitted to the inhibition model within GraphPad, where Table 2 provides an overview 
of the initial rates). (Bottom) Lineweaver-Burk plots indicating a shared intercept for every 
inhibitor concentration, thereby supporting the kinetic analysis regarding the existence of a 







Using the graphical analysis and fits, the kinetic parameters were identified for every inhibitor 
(see Table 7). In this experiment, the value of Km rose for every functionalized dendrimer 
inhibitor, and the value was greatest for the tyrosine system. In this way, the highest level of 
inhibition was associated with the use of the G3.5-OH-Tyr system, where Km was related in an 
inversely proportional way to enzyme affinity for the substrate as illustrated in  Figure 48. The 
values of Ki supported this, which were 95% lower than the inhibition determined for the 
unfunctionalized dendrimer (for the valine and tyrosine systems, respectively). These data 
demonstrate that dendrimer functionalization with tyrosine promotes inhibition. Since α > 1.0, 
the tyrosine dendrimer system evidently operated based on a competitive inhibition 
mechanism. Additionally, α was large, and the trend regarding the size was the same as that 
observed for Km, which was the greatest for the tyrosine system. This demonstrates that the 
enzyme and the inhibitor bind strongly, where the tyrosine dendrimer system (G3.5-OH-Ty) 
was associated with the strongest binding. Figure 48’s Lineweaver-Burk plot, specifically the 
outcome for G3.5-OH-Tyr, provides further support for competitive inhibition.  
From our overall results (Table 8), the data that indicates poor inhibition and therefore, poor 
binding. The valine initial rates for all the substrate and concentrations used were very similar 
to those obtained for the control data. It is clear from Table 9 that the valine dendrimers do not 
bind or inhibit chymotrypsin. Nevertheless, the plots relating to valine concentrations did not 









( μM ) Control 0.4 0.8 1.6 
2.0 0.7158 0.67 0.71 0.625 
4.0 1.18 1.004 1.078 1.008 
8.0 1.562 1.522 1.471 1.309 
Table 8: The summary of initial velocity data in the absence and presence of G3.5-OH-Val . 
Chy at 0.4 µM 
 




























Figure 49: Mixed mode inhibition plots of [BTNA] at various concentrations of G3.5-OH-Val 





























Figure 50: Lineweaver-Burk plots of [BTNA] at various concentrations of G3.5-OH-2HB-LC-
Val at 0.4 µM of Chy. Lineweaver-Burk plots indicating a unshared intercept for every 
inhibitor concentration, thereby indicating the kinetic analysis regarding the existence of a 
uncompetitive inhibition mechanism. 
 
No appropriate functionality is associated with valine that has the capacity to interact (i.e., H-
bonding, π-π, electrostatically), and only weak hydrophobic binding was identified, offering an 
elevated value of Ki amounting to 36.43 μM. These results attest to the significance of 
functionality on molecular interactions regarding binding to the protein surface of Chy, and 
they reflect the importance of the linear chain’s head group. In particular, they show that the 










Inhibitor Km, μM Ki, μM α 
2HB-LC-Val 5.41 36.43 0.16 
2HB-LC -Tyr  15.17 1.51 1.45 
Table 9: Overview of kinetic parameters for every functionalized dendrimer inhibitor 
 
4.3 Inhibition using 3 hydrogen bonding chain 
The inhibition and binding experiments used were the same as applied to the 2 hydrogen 
bonding system and were carried out by a colleague in the group (Dr Azrah Abdul Aziz). The 
first experiment was a control to establish the maxim enzyme velocity using only BTNA and 
Chy in buffer (pH 7.46). This provided the initial rate of the uninhibited reaction (nitroaniline 
production).  We then carried out binding and inhibition experiments using the 3 H-bonding 
linear chains to establish the kinetic data The data is shown below in Figure 51., presented in 
Tables 8 and 9. 
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Figure 51: (a) Mixed mode inhibition and (b) Lineweaver-Burk plots for 3HB-LC-Tyr-Tyr at 
0.4 µM of Chy. 
 
Overall, the data confirmed our predictions regarding amino acid availability and population 
sizes at interfacial/binding areas. In addition, the binding affinity of functionalized dendrimers 
also showed that the 3HB-LC-Tyr bound chymotrypsin much more strongly than the 2HB-LC-
Tyr. As before, the 3HB-LC-Val functionalized dendrimers exhibited very little inhibition and 
therefore the weakest binding. Table 10 shows the initial rates at the highest substrate 
concentrations.  At these concentration the tyrosine systems inhibited 48% .  However, the 



































0 8 48 
Table 10: Initial velocity translated into percentage inhibition 
 
 Inhibitor Km, μM Ki, μM α 
3HB-LC-Val 5.50 24.60 0.85 
3HB-LC -Tyr 6.56 1.23 1.23 
Table 11: Kinetic parameters obtained for all functionalized G3.5-OH with 3 hydrogen 
bonding linear chain 
 
Table 11 summarises the kinetic and inhibition results which were obtained by varying substrat 
concentrations and applying the same kinetic analysis described for the 2 H-bonding systems. 
The Km values obtained were lower for 3HB-LC-Val and 3HB-LC-Tyr, indicating that the 3 H-
bonding systems bind to the protein more strongly than the 2 H-bonding systems.  Furthermore, 
the α values and Lineweaver-Burk plots also confirmed that the 3 H-bonding systems were 
competitive inhibitors, with the 3HB-LC-Tyr having an α value of 1.23. 
Dendrimers functionalized with the valine chain showed very weak binding and uncompetitive 
inhibition (α = 0.85). As before, this was expected.  Valine does not contain suitable 
functionality that can interact, whether electrostatically or in terms of H-bonding, aromatic, π-






24.60 µM. In contrast, Tyr exhibited a Ki value of 1.93 µM. The uncompetitive binding 
mechanism was also confirmed from a Lineweaver-Burk plot, which did not show a common 
y-intercept. As before, tyrosine binding was stronger than valine and can be attributed to the 
 interactions, and hydrogen bonding interactions, provided by the tyrosine functionality.  
In addition, the linear chain has an extra hydrogen bond, which maximises its interaction with 
the dendrimer.  Overall, the results confirm the importance of amino acid functionality and the 
level of hydrogen bonding (provided by the chain) on the overall interactions with respect to 
encapsulation and protein binding. 
 
4.4 Comparison of the 1, 2 and 3 hydrogen bonding linear chains 
At this stage, it is worth comparing the results obtained so far with respect to the number of H 
bonding group along the linear chain and the effect on binding affinity.   The 1HB-LC-Tyr did 
not encapsulate into the dendrimer very well and was not used in any protein binding 
experiments.  However, comparing the 2HB-LC results against those obtained for the 3HB-LC 
systems conformed the importance of maximising dendrimer/linear chain interactions.   
Comparing the results from these two systems allows us to qualitatively determine the 
contribution of the H bonding chains to any overall involved in protein binding (enzyme 
inhibition).  When comparing the valine systems, it is clear that there is no significant 
difference  between 3HB-LC and 2HB-LC when inhibiting or binding the protein.  This is due 
entirely to the overall poor protein binding demonstrated for both systems.  However, there 
was a significantly different result for the tyrosine systems.  Although reasonable levels of 
inhibition were observed for the 2HB-LC-Tyr chain (with α and Ki values of 1.45 and 1.51 µM, 






values of 1.95 and 1.23 µM, respectively - Table 10). The difference in Ki for the 2 and 3 H-
bonded tyrosine chains was nearly 25%. This confirms that the number of H-bonds along the 
linear chain is an important factor with respect to protein binding and complex stability.   
 
Inhibitor 
Head Group of 
amino acid 
Km, μM Ki, μM α 
 
2HB-LC 
Val 5.41 36.43 0.16 
Tyr 15.17 1.51 1.45 
3HB LC 
Val 5.50 24.60 0.85 
Tyr 6.56 1.23 1.95 
Table 12: Kinetic parameters obtained from a linear fit of data for the enzyme catalysed 


















4.5 Conclusions    
 
This study’s aim was to exploit non-functionalized dendrimers and to incorporate targeting and 
binding groups non-covalently into the dendrimer surface. . This included hydrophobicity and 
the effect of any additional binding with one hydrogen bonding linear chain (1HB-LC), two 
(2HB-LC) and three hydrogen bonding (3HB-LC) were studied. Another aim was to investigate 
how these linear chain functionalized with different amino acids could moderate binding. 
Several linear chains were synthesised and encapsulated within the dendrimer to give the 
functionalized system. . A 10-nm bathochromic shift was observed in λmax when 2HB-LC-
Tyr or 2HB-LC-Val  were encapsulated within the dendrimer and a 5 nm bathochromic shift 
was observed for 3HB-LC-Tyr and 3HB-LC-Val.This shift is consistent with a change in 
environment, as the water solvating the linear chains is replaced by the dendrimer’s interior 
groups. The encapsulation levels depended on the number of hydrogen bonding sites along the 
chain, with the 3 H-bonding system being encapsulated better than the 2 H-bonding systems.  
The importance of maximising hydrogen bonding interactions between the linear chain and the 
dendrimer were also observed in protein binding experiments (enzyme inhibition).  Overall the 
best system was the dendrimer encapsulated 3HB-LC-Tyr system, which had a Ki value of 1.23 
M, which was 25% better than any other system.  In addition, the results verified the 
significance of tyrosine as a protein targeting group. It was important to confirm that the 
individual components did not inhibit the enzyme. This was achieved through control 
experiments, which  showed that the both dendrimer and linear chain were required for binding.  






The results support our original hypothesis that a neutral dendrimer can be functionalized non-
covalently using a targeting group that can be encapsulated within a neutral (non-binding) 
dendrimer.    The next stage of the study will be examination of other targeting groups, as well 
as targeting and binding other proteins.    
 
4.6 Future works 
Further studies in this field should seek to develop novel, multivalent dendrimer chain 
complexes containing 3 H-bonding groups functionalized with a series of different amino acids, 
as well as different dendrimers, which can then be mixed together to form optimized 
dendrimer/protein complexes, as shown in Figure 52. After successful encapsulation, the  
system will need to be cross-linked to fix the structure of the dendrimer bound ligand and the 
protein removed, thereby generating a protein ligand that can be collected and used a protein 
ligand for a number of different applications, including use as a therapeutic molecule.      
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CHAPTER 5  
An orthogonal supramolecular 
approach towards protein binding and 
protein sensing using dendrimers as 
scaffolds for the non-covalent 















Developing macro-ligands that can interact with the very large binding surfaces of proteins, is 
a useful strategy for inhibiting unwanted or disease related protein-protein complexes.  
Although covalently functionalized macromolecules have shown significant promise in this 
area, they are often difficult to synthesize and functionalize, particularly with respect to 
controlling the relative position and 3D geometries of binding and targeting groups. In this 
paper we report a new paradigm towards these aims, through a modularized, non-covalent self-
assembly of binding and sensing units within and around an inert dendrimer scaffold.  Although 
embedded within the dendrimer, the binding units are mobile and free to move.  As such, when 
a target protein is added to the solution, the binding units readjust their position to maximize 
any (cooperative) interactions with the protein’s binding surface.  This dynamic process is 
controlled by the protein, as it guides and controls the formation of its own optimized 
macromolecular ligand. We describe the synthesis of the component parts, along with the 
assembly process.  When binding and “sensor units” are combined and included in the 
assembly program, binding could also be detected and quantified.  Binding and control 
experiments using unfunctionalized and non-covalently functionalized dendrimers are 
reported.  Although no binding could be detected using the dendrimer, sensing or binding were 
used alone, very strong binding was observed when all components were used and allowed to 
self-assemble (the dendrimer, tyrosine functionalized chains and a sensing porphyrin).  The 
resulting complex bound cytochrome-c with a Kd of 32 nM, as determined using fluorescence 







5.1 Introduction and Aim 
 
The complexes formed when proteins interact with proteins or other biological 
macromolecules, play essential roles in all biological processes.1 Unwanted or uncontrolled 
interactions, as well as conditions leading to protein mutations, often result in disease.2 These 
include neurodegenerative diseases such as Alzheimer’s and Huntington’s disease.3 Protein-
protein interactions are also involved in viral and bacterial infections.  For example, binding 
between proteins on the surface of bacteria and cells can facilitate internalization (of the 
bacteria) within the host cell.4 Using a similar mechanism, it has been demonstrated that viral 
proteins can bind to host proteins, resulting in internalization and infection.5  As such, 
understanding how to modulate or inhibit protein-protein interactions is an emerging concept 
in drug design.  
 
Proteins recognize each other through complementary functionalities positioned at precise 
points on large interacting surfaces that can range from 500 Ǻ2 to 5000 Ǻ2; the key component 
of which is known as the “hot spot” or interfacial area.6 Therefore one challenge in designing 
inhibitors is the construction of architectures that are large enough to interact with most, or all, 
of the interfacial area of a protein.7 As well as size, an array of non-covalent interactions are 
also important with respect to an inhibitor’s selectivity, including charge/charge, hydrophobic, 
aromatic/π−π interactions and hydrogen bonding.8 Studies into protein-protein interactions 
have identified specific amino acids that consistently contribute more than 2 kcal/mol to the 






These amino acids are capable of making multiple interactions and include; tryptophan 21%, 
arginine 14% and tyrosine 13%.   As such, multi/polyvalency, functionality, charge and size 
are key design determinants with respect to obtaining selective ligands for protein binding.  
Given these requirements it is not surprising that macromolecular ligands show great promise 
with regards to protein binding.  Examples include calixarene and porphyrin scaffolds,10,11 
nanomaterials,12 and linear polymers.13,14   
 
We have studied the use of dendrimers and functionalized dendrimers as protein binding 
ligands.15,16  These macromolecules can be constructed in specific sizes and are capable of 
binding to a range of protein binding interfacial areas/hot-spots.  Our preliminary studies 
involved a series of negatively charged carboxylate dendrimers designed to interact with 
proteins possessing positively charged interfacial areas of various sizes. The results revealed 
that selective binding could be achieved by matching the dendrimer’s size/maximum 
addressable area, with the protein’s interfacial or binding area.15 We then investigated the 
importance of terminal group functionality on binding affinity using dendrimers functionalized 
with tyrosine.  Binding experiments indicated that the tyrosine dendrimer binds chymotrypsin 
with an affinity around 30% stronger than an unfunctionalized dendrimer of similar size and 
charge.17 These results were extended further, using a porphyrin cored dendrimer whose 
fluorescence was quenched when bound to cyctochrome-c.18  Overall, these experiments 
demonstrated the importance of size and functionality when designing macromolecular ligands 
for selective protein binding.  Although these results were successful and demonstrated a clear 






specific terminal groups and core functionality.  In addition, errors in design or synthesis could 
not be corrected easily, requiring a new macromolecular/dendrimer ligand to be synthesized.  
Furthermore, although adding a single/specific functional group many times to the surface of 
the dendrimer is relatively easy (polyvalency), it is extremely difficult to position such moieties 
in respect to each other with geometric precision. It is even more difficult to add a number of 
different functional groups (multivalency) with control regarding their relative position to each 
other:  Yet, any therapeutically useful macromolecule will require such precision in its design.  
Towards this aim, we developed a non-covalent methodology for the assembly of targeting and 
sensing units within and around a dendrimer scaffold.  Control over the relative position of 
targeting groups can be achieved using a target protein as a template, directing formation of an 
optimized macromolecular protein ligand through various reversible cooperative interactions. 
In this paper we describe this new methodology and show how non-covalent combinatorial 
chemistry can be used to simultaneously functionalize a dendrimer with targeting and sensing 
groups. Through this approach, a dendrimer that cannot intrinsically bind or interact with a 
protein, can be used as a scaffold to support various binding and sensing components within 












5.2 Results and Discussion 
 
5.2.1 Design and synthesis of materials. 
 
The new approach uses non-covalent chemistry to assemble an optimized macromolecular 
ligand around a protein template.  The design and methodology is shown schematically in 
Figure 1. The dendrimer, its binding units and a sensing component are added to water, where 
they can assemble into the random complex 1.  When a protein is added, the randomly 
distributed binding units are free to move within the dendrimer and maximize any cooperative 
protein-binding interactions. Binding can then be detected and quantified via perturbation of 
an encapsulated sensing group’s photophysical properties.   
 
Figure 1: Schematic showing the proposed self-assembled protein binding complex 1 and its binding to a target 
protein.  A neutral/non-binding dendrimer acts as a scaffold to support and encapsulate the binding and sensing 
units.  The use of non-covalent chemistry allows the targeting groups to move and maximize their binding 








This design concept requires three separate components as shown in Figure 2.  With respect to 
the dendrimer, it must be water-soluble, to ensure that the protein and the assembled ligand are 
in the same aqueous phase.  In addition, the dendrimer’s terminal groups must be neutral and 
inert. This is vitally important, as the dendrimer must not react, bind or interact in any way 
with the protein’s binding surface (in the absence of any encapsulated functionality). 
Additionally, the dendrimer needs to be large enough to address the full size of the target 
protein’s binding/interfacial area, whilst also ensuring that incorporation of the binding/sensing 
units are not prevented or limited by a dense shell or dense packed structure.19,20   For this work 
we selected cytochrome-c as the target protein.  The structure of this protein is well known, 
having a binding interface (hot-spot) around 1100 Å2 in size.21   As such, the neutral G3.5 
PAMAM dendrimer 2, with 32 terminal OH groups 22 and a maximum addressable area around 
1200 Å2 was selected as the scaffold unit.23,15  
The second component, is the targeting or binding units that will be encapsulated/incorporated 
within the dendrimer’s interior. A cooperative combination of hydrophobic, electrostatic and 
H-bonding interactions were chosen to drive encapsulation.  To achieve this, a series of 
hydrophobic oligomeric amide chains, terminated with an amino acid (the binding 
functionality) were selected.  For this proof of principle work,  tyrosine terminated chains 22 
and 26, with 2 or 3 hydrogen bonding groups were was selected as the binding/recognition 
motif and valine terminated chains 24 and 28 selected as controls.  These amino acids are 
known respectively to contribute significantly well, or extremely poorly, to protein-protein 
interactions.9 The oligomeric amide chains were synthesized from propyl amine and the 






giving the final amide linked linear chains, LC-Tyr 22/26 and LC-Val 24/28, after a simple 
deprotection step, Figure 53.   
 
Figure 53: The three components involved in formation of the self-assembled macromolecular 
protein ligand 1. 
 
The final component of the self-assembled system 1 is simple porphyrin that can be used as the 
sensing/detection unit.   As well as possessing a well-characterized binding area and a size 
compatible with the scaffold dendrimer 10, cytochrome-c is a porphyrin containing protein that 
emits a strong fluorescence signal that can be perturbed by a bound quencher.  This property 






within the interior of the dendrimer.  It is essential that this quencher does not bind to the 
protein independently and is retained within the dendrimer.  As such, zinc-tetra-4-
hydroxyphenyl porphyrin 29 (Zn-THPP) was selected as the internal quencher.  Zn-THPP 29 
is hydrophobic and although it is almost insoluble in water,24  it can be encapsulated within the 
dendrimer using simple hydrophobic interactions.25  In addition, porphyrin 29 has a central 
metal that can coordinate to the dendrimer’s internal amines.  Porphyrin 29 also has four 
phenolic OH groups that can hydrogen bond to the dendrimers amides.  In addition, the OH 
groups are acidic enough to be deprotonated by the internal amines, resulting in additional 
electrostatic interactions.25  As such, there are a number of cooperative interactions that will 
help ensure porphyrin 29 stays encapsulated within the scaffold dendrimer 10.  Zn-THPP 29 
was obtained easily in three steps, starting from 4-methoxybenzealdehyde and pyrrole.  
 
5.2.3 Encapsulation and self-assembly of protein binding units. 
 
Encapsulation of the linear chains and the sensor unit within the G 3.5-OH dendrimer 10, was 
achieved using a procedure similar to that used to solubilize and encapsulate hydrophobic drugs 
within water soluble PAMAM dendrimers.25 For the linear chains, 10 equivalents of 22/26 or 
24/28 were added to methanolic solutions of dendrimer 10. The methanol was removed and a 
known volume of buffer (0.01M PBS, pH 7.4) was added, to give a final dendrimer 
concentration of 1×10-6 M.  The solution was then filtered to remove any undissolved material.  
Beer Lambert analysis confirmed that all 10 linear chains had been encapsulated, giving a final 
concentration of 1×10-5 M for 3HBLC-Tyr 26 and 3HBLC-Val 28.  This is higher than the 






0.58×10-5 M LC-Val 4). Furthermore, a 5 nanometre bathochromic shift was observed in max 
when either LC-Tyr 22/26 or LC-Val 24/28 were encapsulated within the dendrimer  as shown 
in Figure 54 and in Figure 55, respectively. 
 
Figure 54: UV spectra (buffer-pH 7.4) of the free and encapsulated 3HBLC-Tyr 26 chain 
 
 










































  This shift is consistent with a change in environment, as the water solvating the linear chains 
is replaced by the dendrimer’s interior groups.  For the 3-H bonded systems, the solubility and 
spectroscopic data confirmed that all 10 linear chains were encapsulated within the dendrimer.  
For the 2-H bonded system, spectroscopic data revealed that between 5 and 6 chains had been 
encapsulated.  Again, encapsulation was demonstrated and confirmed by shifts in max.    It is 
assumed that the driving force for complexation was a cooperative process involving 
hydrophobic and H-bonding interactions, Figure 56.   The methodology is similar to that used 
by Meijer to construct dendrimer complexes that could aggregate on dilution.26 
 
 
Figure 56: Schematic showing a segment of the G3.5-OH dendrimer 10 and possible H 
bonding motif to the linear chain, 3HBLC-Tyr 26. 
 
A similar procedure was used to encapsulate the porphyrin-signalling unit Zn-THPP 5.   In this 
case, one equivalent of Zn-THPP 29 was added with respect to dendrimer.  Concentration was 
determined by UV,27 which confirmed a 1:1 stoichiometry for the Zn-THPP/dendrimer 






which shifted from 412 nm to 425 nm.  This shift is a characteristic of complexation (between 
Zn and the dendrimer’s internal nitrogens) and confirms encapsulation within the dendrimer.  
Having established and quantified encapsulation of the various components, the next step 
involved a series of binding experiments to test whether or not the self-assembled complex 
could bind to cytochrome-c and be detected. 
 
5.2.4 Protein interaction and quantification of binding affinities for the 2-
H bonding system. 
 
Protein binding experiments were attempted using the 2-H bonding system.  Titrations using 
the same methods described above, did not show any changes in intensity for the porphyrin 
emission peak when the dendrimer/LC complex was added.  As such, the 2-H bonding systems 
do not appear to bind.   
 
5.2.5 Protein interaction and quantification of binding affinities for the 3-
H bonding system. 
 
Binding experiments were carried out on the 3-H bonding system at pH 7.4 by titrating 
solutions of cytochrome-c into a solution of the dendrimer complex 1 assembled from all three 
components in a1:1:10 ratio for dendrimer 10, Zn-THPP 29, and linear chain 26 or 28 
respectively (1×10-6 M for dendrimer and Zn-THPP and 1×10-5 M for linear chain).  Detection 
and quantification of binding was observed by following changes in the intensity of the Zn-
THPP 29 emission band at 610 nm, which is quenched if cytochrome-c binds.15 Our initial 






cytochrome-c were added, a significant reduction in the emission peak at 610 nm was observed, 




Figure 57: Emission spectra reduced after addition of each aliquot of a 1.0 µM Cyt-c to a 











Figure 58: Titration plots showing changes of intensity for the Zn-THPP 29 peak at 615 nm 
when cytochrome-c was added (excitation at 410 nm).  
 
The change in intensity vs cytochrome-c concentration was plotted and the data fitted to a 1:1 
binding model (Graphpad) and a dissociation constant (Kd) of 32 nM was obtained, (Figure 
58).   
Despite the fact that our self-assembled system does not possess any negative charges, that 
could interact with cytochrome-c’s positive rich surface (and strengthen the overall 
interaction), binding was comparable to data reported for other surface binding ligands and 
cytochrome-c.  For example, Hamilton reported Kd values between 120 and 20 nM for various 
porphyrins possessing up to 8 terminal negative charges.28 Similarly, Wilson observed 
dissociation constants ranging from 23 to 2 nM for a series of metal ligands, again possessing 
a number of terminal negative charges.29 Therefore, as our system does not possess any 
negative charges, binding must come from other features that combine cooperatively to give 
the high binding affinity observed.  These include  stacking, hydrogen bonding and 
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hydrophobic interactions from the tyrosine linear chain, as well as the possibility of additional 
hydrogen bonds from the dendrimer. 
The experiments were then repeated using a dendrimer complex containing the linear chain 
functionalized with valine (3HBLC-Val 28), an amino acid not normally associated with 
protein-protein binding.9 On this occasion, the intensity of the porphyrin fluorescence did not 
change as cytochrome-c was titrated into the dendrimer complex, indicating that binding did 
not take place, Figure 58.  The concentration of cytochrome-c was increased, but again no 
reduction in porphyrin intensity was observed.  As valine is not favoured with respect to surface 
protein binding, this result was expected.  However, the result represented a useful control that 
confirms the orientation of the amino acid chains within the dendrimer.  Specifically, that the 
tyrosine head groups point out from the dendrimer when binding to the protein surface, as 
shown schematically in Figure 59(a).  If this were not the case and the tyrosine and valine head 
groups were buried within the dendrimer, then both linear chains (LC-Tyr and LC-Val) would 
present the same functionality at the dendrimer surface, as shown schematically in Figure 5 
(b). This would result in an identical dissociation constant being determined for 3HBLC-Tyr 








Figure 59: There are two extreme binding orientations possible for the linear chains.  (a) All 
of the head groups pointing out enabling interaction with the protein surface.  If this occurs, 
then binding will be different for different head groups (observed).  (b) An alternative 
orientation with the tails pointing out, which then bind to the protein surface.  If this occurs, 
then binding would be identical for different head groups (not observed). 
 
5.2.6 Control experiments 
 
A series of additional controls were carried out to confirm that binding was taking place via 
the self-assembled process shown in Figure 60.  These included the addition of cytochrome-c 
to a solution of a dendrimer-porphyrin complex (no linear chains), which showed no change in 
the porphyrin emission intensity, and therefore no binding, Figure 60(a).  A control using just 
Zn-THPP 29 was difficult, due to its lack of solubility.  However, a saturated solution showed 
a very weak emission that was not quenched when cytochrome-c was added, confirming that 
the porphyrin did not bind independently to the protein, Figure 60 (b).  A final control using 






Zn-THPP 29 solution, did not show any evidence of quenching or bonding when cytochrome-
c was added, Figure 60 (c).   
 
Figure 60: Control experiments indicated that binding was not detected when the 

















In conclusion, we have demonstrated a macro supramolecular methodology that has the 
potential to generate new ligands that can bind selectively or specifically to the large interfacial 
binding areas found on the surface of target proteins.  Although covalently functionalized 
macromolecules showed promise in this area, it can be difficult to functionalize their surfaces 
and impossible to control their relative position with respect to any 3 dimensional geometric 
requirements (of the functional groups).   
To overcome these problems, we developed a supramolecular methodology for the 
construction of macromolecular protein ligands that can bind and detect proteins.  The 
methodology involved a dendrimer scaffold that could support a targeting/binding group, as 
well as a sensing groups via encapsulation.  Encapsulation was achieved through a combination 
of hydrophobic, electrostatic and hydrogen bond interactions.  Specifically, linear amide chains 
terminated with tyrosine and valine (amino acids known respectively to contribute significantly 
or poorly to protein-protein binding affinities).  Self-assembled complexes were constructed 
using a 10:1 ratio of the linear chains and dendrimer.  Encapsulation resulted in an increase in 
the linear chain’s aqueous solubility and complexation was confirmed through UV, which 
indicated a 5 nm bathochromic shift in the linear chains max.   
Complexes containing the targeting groups and a sensing unit were obtained by adding a 
hydrophobic, insoluble porphyrin (1 equivalent with respect to dendrimer).  UV analysis 
indicated that the porphyrin was soluble and that encapsulation was successful.   Protein 
binding was subsequently assessed using cytochrome-c as a test protein, which was titrated 






linear chain systems were analysed, specifically linear chains with 2 or 3 H bonding groups.  
No binding was observed for the 2-H bonding system, but better results were obtained for the 
3-H bonding.  This is due to the stronger overall binding possible for the system with more H-
bonding interactions.   
Although the valine complex did not show any binding for the 3-bonding system, the tyrosine 
complex bound the protein with a very strong affinity, giving an binding constant of 3.13 ×108 
M-1 (Kd = 32 nM). Control experiments using a dendrimer/porphyrin complex without linear 
chains showed no evidence of binding.  Similar results were obtained for controls involving, 
the (dilute) porphyrin, the linear chains or solutions of the porphyrin and linear chains.  The 
methodology described is essentially modular in approach, which means that the same scaffold 
can be used to bind and sense a number of different proteins and only the binding and/or sensing 
components need to be changed.  Alternatively, the same binding and/or sensing units can be 
used with a variety of dendrimers of differing size and/or sensing units.  Therefore, this method 
will allow libraries of dendrimer scaffolds, binding groups and sensing units to be prepared, 
which can then be combined in an almost infinite array to target many different types of protein.  
As well developing methods to fix or trap the linear chains within the dendrimer, future 
experiments will also involve combining a number of different targeting groups and studying 










Materials.  All reagents and solvents were obtained from commercial sources (primarily 
Sigma- Aldrich) and were used without further purification. Dry solvents were obtained from 
the University of Sheffield Chemistry Department Grubbs solvent dispensing system. All 
glassware was cleaned and dried in an oven overnight (100 °C) before use.  
UV Spectrophotometry.  Absorbance was recorded on an Analytic Jena AG Specord s600 
uv/vis spectrometer and analyzed using WinASPECT.    Infra-red spectroscopy. IR spectra 
were recorded using a Perkin-Elmer UATR Infrared spectrometer. Spectra were analyzed with 
Spectrum100 software and positions of peaks are stated as wave numbers (cm-1). Fluorescence 
spectroscopy Emission was recorded on a Perkin Elmer Fluoromax-4 Spectrofluorometer at 
25 °C, Spectra were analyzed with FluorEssence V3software.  NMR Spectroscopy.  All NMR 
samples were prepared using deuterated solvents supplied by Sigma Aldrich. 1H NMR and 13C 
NMR spectra were recorded using a Brucker AV1400 MHz machine. Chemical shifts are 
quoted using ppm, coupling constants are quoted in Hertz referenced to residual solvent signals. 
The NMR spectra were analyzed using Topspin 3.0 NMR software. Mass Spectrometry. For 
dendrimers, a Bruker reflex III MALDI-ToF mass spectrometer was used.  For all other 
samples, a Waters LCT Premier XE spectrometer, and Electrospray Ionization (ES) was used.  









 5.4.1 Synthesis of PAMAM dendrimer 
 
G0.5 PAMAM dendrimer 1 
Instead of the full generation dendrimer, a mixture of ethylenediamine (EDA; 10 mL,  0.15 
mol), methyl acrylate (57 mL, 0.63 mol) and methanol (50 mL) was stirred for 24 h according 
to the standard protocol for the synthesis of the half-generation dendrimer (G0.5 PAMAM). 
The mixture was then washed as described above to obtain the desired product in the form of 
a yellow oil (64.0 g, 106 % residual solvent). The product was characterised as follows:  
FTIR (νmax/cm
-1): 2952, 2826,1730,1170 ; 1H NMR (,400 MHz,  MeOD): 2.48 (8H, t, J  7.0), 
2.54 (4H, s), 2.78 (8H, t, J 7.0), 3.68 (12H, s); 13C NMR (,400 MHz, MeOD): 32.0, 49.5, 51.6, 
50.7 ,173.3; MS (ES), Calculated for C18 H32 N2 O8  = 405 (MH
+) found 405 
G1.0  PAMAM dendrimer 2 
 
A mixture of the G0.5 PAMAM dendrimer (53.0 g, 0.13 mol,), EDA (175 mL, 2.6 mol) and 
methanol (230 mL) was stirred for 4 days according to the standard protocol for the synthesis 
of the full generation dendrimer. The mixture was then washed as described above to obtain 
the desired product in the form of a sticky, viscous, dark amber oil (70.9 g, 106% residual 
solvent). The product was characterised as follows: 
 FTIR (νmax/cm
-1): 3276 ,2926, 2816 ,1635 , 1547 ,1029 cm-1; 1H NMR ( 400 MHz,  MeOD): 
2.39 (8H, t, J 7.0), 2.56 (4H, s), 2.73 (8H, t, J 6.0), 2.78 (8H, t, J 7.0), 3.27 (8H, t, J 6.0), 3.37 
(4H, s); 13C NMR (400 MHz, MeOD): 33.3, 41.6, 49.9 , 51.0 MS (ES), Calculated for C22 H48 
N10 O4  516 (MH
+) found 516 
G1.5 PAMAM dendrimer 3 
A mixture of the G1.0 PAMAM dendrimer (38.5 g, 0.07 mol), methyl acrylate ( 107 mL, 1.18 
mol) and methanol (350 mL) was stirred for 48 h according to the standard protocol for the 
synthesis of the half-generation dendrimer. The mixture was then washed as described above 
to obtain the desired product in the form of a brown oil (74.4 g, 88%). The product was 






 FTIR (νmax/ cm
-1): 3300 ,2951 , 2826 , 1731 , 1643 1534 .1034; 1H NMR ( 400 ,  MeOD): 2.41 
(8H, t, J  7.0),  2.48 (16H, t, J  7.0), 2.57 (8H, t, J 6.5), 2.63 (4H, s), 2.80 (24H, m), 3.27 (8H, 
t, J 6.5), 3.37 (4H, s) 3.69 (24H, s); 13C NMR (400 MHz, MeOD,):  50.8, 52.3, 50.9, 49.8, 37.1, 
33. 32.2, 173.3 ; MS (ES), Calculated for C54H96N10O20 = 1205 (MH
+) found 1206 
G2.0 PAMAM dendrimer  4 
A mixture of the G1.5 PAMAM dendrimer (63.7 g, 0.053 mol,)  EDA (283 mL, 4.23 mol) and 
methanol (250 mL) was stirred for 7 days according to the standard protocol for the synthesis 
of the full-generation dendrimer. The mixture was then washed to obtain the desired product 
in the form of a viscous, sticky, dark amber oil (86.7 g, 114% residual solvent). The product 
was characterised as follows: FTIR (νmax/ cm
-1): 2916, 2811 ,1635 cm-1, 1530 , 1030 cm-1; 1H 
NMR (400 MHz,  MeOD): 2.39 (24H, t, J   6.5), 2.60 (12H, m), 2.75 (16H, t, J  6.5), 2.82 (24H, 
tr, J 7.0),  3.27 (24H, t, J 6.5), 3.37 (12H, s); 13C NMR ( 400 MHz, MeOD): 52.1, 49.8, 41.6, 
40.7, 37.3, 33.4, 33.2 ,173.8 ,173.4 ; MS (ES), Calculated for C62 H128 N26 O12 = 1429 (MH
+) 
found 1430 
G2.5 PAMAM dendrimer 5. 
A mixture of the G2.0 PAMAM dendrimer (, 52.0g, 0.036 mol), methyl acrylate ( 105 mL, 
1.16 mol) and methanol (350 mL) was stirred for 72 h according to the standard protocol for 
the synthesis of the half-generation dendrimer. The mixture was then washed to give the desired 
product in the form of a viscous, brown oil (87.3 g, 86 %). The product was characterised as 
follows: FTIR (νmax/ cm
-1): 3292, 2818 , 1731, 1643 , 1534 cm-1; 1H NMR ( 400 MHz,  MeOD):  
2.40 (24H, J 7.0),  2.49 (32H, t, J  7.0), 2.61 (28H, m), 2.82 (56H, m), 3.28 (24H, t, J 6.5), 3.37 
(12H, s) ,3.69 (48H, s ); 13C NMR (400 MHz ,MeOD):  50.8 , 52.4, 52.1, 49.7, 48.5, 37.3, 37.1, 
33.4, 33.2, 32.2 ,173.3 ; Calculated for C126 H224 N26 O44  2807 (MH
+) found 2808 
G3.0 PAMAM dendrimer 6 
A mixture of the G2.5 PAMAM dendrimer (44.1 g , 0.0157 mol), EDA (2.51 mol, 168 mL) 
and methanol (200 mL) was stirred for 6 days according to the standard protocol for the 






product in the form of a sticky, viscous, dark amber oil (51.3 g, 100%). The product was 
characterised as follows: FTIR (νmax/ cm
-1): 3275, 3070 ,2929, 2819, 1634,1544 ,1031; 1H NMR 
(400 MHz, MeOD): 2.39 (56H, t, J 6.5),  2.60 (28H, m), 2.74 (24H, t, J  6.5), 2.81 (56H, t, J 
6.5), 3.27 (56H, t, J  6.5) , 3.37 (28H, s); 13C NMR (400 MHz, MeOD):  52.1, 49.7, 41.7, 40.7, 
37.2, 33.4 ,173.7 173.3 ; Calculated for C142 H288 N58 O28  3256 (MH
+) found 3257 
 
 5.5 Synthesis of Functionalised PAMAM 
PAMAM G3.5-OH dendrimer 
A PAMAM G3.5 dendrimer (11.08g, 1.84 mmol) with 32 terminal methyl ester groups was 
dissolved in 8 mL of anhydrous DMSO containing potassium carbonate (9.00 g, 66 mmol).  
Ethanolamine (4.42 g, 72 mmol) was added and the mixture stirred and heated at 50 oC for 72 
hours.  The crude product was filtered under reduced pressure to remove the solid residues and 
the solution transferred to a large conical flask.  Acetone (600 mL) was added and the crude 
product formed a thick oil/paste at the bottom of the flask. The acetone was decanted off 
carefully and enough distilled water added to dissolve the product (5 mL). The product was 
precipitated using the minimum amount of acetone and allowed to settle.  The initial solid 
product proved to be hydroscopic and quickly became a paste when left.  The acetone was 
decanted off and the precipitation procedure repeated once more. The product was dissolved 
in methanol and transferred to a round bottomed flask, where the solvents were removed under 
vacuum to give the final PAMAM-G3.5 OH dendrimer as a pale yellow/cream paste in 90%.   
FTIR (νmax/cm
-1), 3265, 3072, 2918, 2826, 1640, 1549; 1H NMR (400 MHz, D2O), 3.56 (62H, 
t, J  7.0), 3.25 (120H, m), 2.75 (120H, m), 2.55 (60H, t, J 7.0),  2.36 (120H, m); 13C NMR (100 
MHz, D2O), 175.1,  174.5, 61.5,  60.0, 52.0 , 49.0, 44.0, 42.0 , 37.0 ,  33.0; MS (ES), Calculated 









5.5.1 Synthesis of two hydrogen bonding linear chain. 
 
Boc- β-alanine 12 
β-alanine (6.06 g, 0.067 mol) was dissolved in 120 mL of 1:2 1M NaOH:THF and acetic 
anhydride (14.77 g , 0.067 mol) was added to form a cloudy solution. This was stirred at room 
temperature for 22 h, then concentrated under vacuum prior to the addition of 100 mL each of 
water and diethyl ether. The solution was then acidified with 4M aqueous HCl (pH 1.7) to 
obtain a precipitate, followed by the addition of diethyl ether (100 mL) and washing twice with 
water (100 mL) and twice with brine (175 mL). The organic layer was collected and dried over 
magnesium sulphate prior to filtration and vacuum concentration to obtain a clear, viscous oil. 
Finally, this was allowed to stand overnight under ambient air to obtain the white solid (6.46 
g, 50 %). The product was characterised as follows  
FTIR (vmαx/cm
-1) 3440, 1704; 1H NMR ( 400 MHz, CDCl3): 3.44 (2H, t, J  6.7), 2.54 (2H, t, J  
6.7), and 1.43 (9H, s); 13C NMR (400 MHz, CDCl3): δ = 34.3, 156.2, 28.2, 28.2, 28.2 175.2, 
80.4, and 36.3; MS (ES), Calculated  188 [MH+] found 212.1 (ΜΝa+) and 188.1 (ΜΗ+). 
Boc-protected of amide 13 
Heptylamine (1.5 ml, 0.010 mol,), triethylamine (0.020 mol, 2.8 ml,), 4-
Dimethylaminopyridine (DMAP, 1.479 g, 0.012 mol) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) hydrochloride (2.320 g, 0.012 mol) were added to 
a solution of Boc- β-alanine (1.91 g, 0.010 mol) in dichloromethane (DCM, 100 mL) to obtain 
a clear, colourless solution. After stirring for 24 h at room temperature, the solution was 
washed, dried, and allowed to stand overnight under ambient air to obtain a white powder 
(0.775 g, 27 %). The product was characterised as follows:  
FTIR (νmax/ cm
-1): 3332,1718, 1680; 1H NMR (400 MHz, CDCl3): 3.44 (2H, t, J 6.0), 3.38 (2H, 
t, J 7.0), 2.42 (2H, triplet, J 6.5),  1.49 (2H, m),  1.45 (9H, s), 1.32 (8H,m), 0.95 (3H, t, J 7.0),  
5.20 (1H, s),  5.70 (1H, s); 13C NMR (400 MHz, CDCl3):  39.3, 80.4, 27.2, 37.2, 32.4, 29.0, 
28.2, 28.2, 28.2, 156.2, 35.3, 29.41, 22.6, 168.7 and 14.0; (LC-MS): calculated for  C15H30N2O3 






Deprotected Amide chain 14 
Trifluoroacetic acid (TFA; 5 mL, 0.066 mol) was added to a solution of 13 (0.645 g, 0.0023 
mol) in DCM (6.4 mL) and stirred for 23 h to obtain a clear, yellow solution. The TFA and 
solvent were then removed to give a viscous orange oil (1.027, 240 % residual solvent). The 
product was characterised as follows:  
FTIR (νmax/cm
-1): 3332  1689 ; 1H NMR (400 MHz, CDCl3):  3.18 (2H, t, J 7.4), 2.83 (2H, t, J 
6.6),  2.24 (2H, t, J 6.6), 1.69 (2H, m), 1.30 (8H, m), 0.90 (3H, t, J 7.0); 13C NMR (400 MHz, 
CDCl3): 14.0, 168.7, 32.4, 34.7, 40.1, 29.0, 27.2, 39.3, 29.4 and 22.6; (LS-MS): calculated for 
C10H22N2O  186,  found 187 [MH
+] 
Boc-tyrosine linear chain 21  
From the deprotected of amide 14 (1.0 g, 4.98 mmol), Boc-tyrosine-OH (1.4 g. 4.98 mmol), 
EDC hydrochloride (0.78 g, 4.0 mmol), DMAP (1.21 g, 9.96 mmol) and triethylamine (1.52 g, 
0.015 mol). The crude product (a pale-yellow solid) was purified by silica chromatography 
using a DCM/1% MeOH eluent to obtain the desired product in the form of a white powder 
(1.5 g, 71%). The product was characterised as follows:  
FTIR (νmax/cm
-1),3305, 2968 , 2950, 2878 , 1688,1645, 1502, 1H NMR (400 MHz,  
CDCl3):7.12 (2H, m, J  8.0),  6.71 (2H, m, J  8.0),  4.72 (1H, t, J 6.5),  3.65 (2H, q, J 7.5), 3.36 
(2H, m),  3.26 (2H, m) 2.48 (2H, t, J  6.5), 1.56 (3H,t, J  7), 1.45 (9H, s),  1.28 (8H, m)  0.90 
(3H, triplet, J 7.0); 13C NMR ( 400 MHz,  CDCl3):  172.7, 168.7, 157.8, 155.3, 130.4, 130.4, 
128.9, 115.7, 115.7, 80.4, 55.8, 39.3, 38.4, 36.4, 35.2, 32.4, 29.4, 29.0, 28.2, 28.2, 28.2, 27.2, 
22.6 and 14.0. (LS-MS): calculated for C24H39N3O5  450,  found 449 [MH
+] 
Deprotected tyrosine 2HB-LC-Tyr 22 
The deprotected amide 22 from the Boc-protected tyrosine 21 (1.0 g,  2.15 mmol) with TFA 
(10 mL) and DCM (20 mL) to give the desired product in the form of a white powder (510 mg, 
65%). The product was characterised as follows:  
νmax/cm
-1 (FTIR) 3066 , 2904, 1643, 1287, 1231, 1H NMR (400 MHz,  CDCl3): 7.12 (2H, m, J  






2.48 (2H, t, J 6.5),  1.28 (8H, m) , 0.90 (3H, t, J 7.0); 13C NMR (400 MHz, CDCl3):  130.4, 
130.4, 54.3, 39.3, 37.0, 29.0, 157.8, 115.7, 115.7, 126.17, 36.4, 14.0, 171.2, 35.2, 29.4, 27.2, 
22.6, 168.7, 32.4 (LS-MS): calculated for C19H31N3O3  349,  found 350 [MH
+] 
Boc-valine chain 2HB-LC-Val 23 
From the deprotected of amide 14 (1.0 g, 4.98 mmol), DMAP (1.21 g, 9.96 mmol), Boc-Valine-
OH (1.1 g, 4.98 mmol), EDC hydrochloride (0.78 g,  4.0 mmol,) and triethylamine (1.52 g, 
0.015 mol) were added and left for 24 hours. The product was characterised as follows:  
FTIR (νmax/cm
-1) ,   2944 , 1633, 1565, 1333, 1166, 1131; 1H NMR (400 MHz, CDCl3): 4.42 
(1H, d, J 7.0),  3.18 (2H, t, J 7.0), 2.83 (2H, t, J 7.0),  2.24 (2H, t, J 7.0 ),  2.08 (1H, sept, J = 
7.0), 1.56 (2H, t, J 7.0), 1.45 (9H, s), 1.30 (8H ,m), 0.90 (6H, d, J  7.0) and  0.90 (3H, t, J  7.0); 
13C NMR (400 MHz ,CDCl3): 171.3, 168.7, 155.5, 80.4, 57.4, 39.3, 36.4, 35.2, 32.4, 31.4, 29.4, 
29.0, 28.2, 28.21027 28.2, 27.2, 22.6, 18.6, 18.6, 14.0 (LS-MS): calculated for C20H39N3O4  
386,  found 387 [MH+] 
Deprotected valine 2HB-LC-Val 24  
Boc-protected valine 23 (1.0 g, 2.50 mmol), TFA (10 mL) and DCM (20 mL). The desired 
product was obtained in the form of a white powder (435 mg, 58%) and was characterised as 
follows:  
FTIR (νmax/cm
-1) , 2988, 1650, 1562, 1284, 1130, 1H NMR (400 MHz , CDCl3): 4.42 (1H, d, J 
7.0), 3.18 (2H, t, J  7.0), 2.83 (2H, t, J 7.0 ), 2.24 (2H, t, J 7.0 ), 2.08 (1H, sept,  J 7.0), 1.56 
(2H, t, J  7.0 ), 1.30 (8H, m), 0.90 (6H, d, J = 7.0), 0.90 (3H, triplet, J  7.0); 13C NMR (400 
MHz,  CDCl3): 170.6, 168.7, 58.3, 39.3, 36.4, 35.2, 32.4, 30.2, 29.4, 29.0, 27.2, 22.6, 17.9, 











5.5.2 Synthesis of three hydrogen bonding 
 
Boc-protected amide chain  17 
n-propylamine 15 (1.0 g, 0.0169 mol), Boc--alanine 16 (3.41 g, 0.018 mol) and DMAP (4.40 
g, 0.036 mol) were dissolved in DCM (100 mL). EDC.HCl (3.45 g, 0.018 mol) and 
triethylamine (5.17 g, 0.0507 mol) were added and the mixture stirred under nitrogen for 24 
hours. The solution was transferred to a separating funnel and the crude product washed with 
brine solution (3×100 mL) and the aqueous layers extracted with DCM. The organic layers 
were collected and dried with Mg2SO4. The solvent was concentrated under reduced pressure 
and dried under a high vacuum to give the Boc protected chain 17 (3.97 g, 96 %) as a white 
powder. FTIR (νmax/cm
-1) ,   3335, 2968, 1682, 1645, 1528; 1H NMR (400 MHz; CDCl3) 5.85 
(1H, s), 5.25 (1H, s), 3.45 (2H, q, J= 7.0), 3.25 (2H, q, J 7.0), 2.45 (2H, t, J 7.0), 1.55 (2H, m), 
1.45 (9H, s), 0.95 (3H, t, J 7.0); 13C NMR (100 MHz; CDCl3); 172.5, 155.8, 80.5, 41.5, 37.0, 
36.5, 29.0, 23.0; MS (ES), Calculated for C11H22N2O3 [MH+]: 231, found 231. 
Deprotected amide chain 18 
Boc protected chain 17  (3.0 g, 0.013 mol) was dissolved in DCM (25 mL) and TFA (25 mL) 
was added.  The solution was stirred under nitrogen for 24 hours, before being transferred to a 
separating funnel and washed with water (5×25 mL).  The organic layer was collected, dried 
(MgSO4) and then removed using a rotary evaporator. The final product was dried under a high 
vacuum to yield amide chain 18 (1.4 g, 82 %) as a yellow oil, which was used directly in the 
next step.  FTIR (νmax/cm
-1),  2978, 1645, 1558; 1H NMR (400 MHz; D2O) 3.10 (2H, t, J 7.0), 
2.98 (2H, t, J 7.0), 2.51 (2H, t, J 7.0), 1.36 (2H, m), 0.75 (3H, t, J 7.0); 13C NMR (100 MHz; 








Boc-protected di-amide chain 19   
The title compound was synthesized using the method described above for the Boc-protected 
amide chain 19, using the following; EDC.HCl (3.83 g, 0.020 mol), Boc--alanine 16 (3.85 g, 
0.020 mol), deprotected amide chain 18 (2.65 g, 0.020 mmol), DMAP (4.89 g, 0.04 mol), and 
triethylamine (6.11 g, 0.06 mol).  After work up and purification the Boc-protected diammide 
chain 19 was obtained as a white solid (4.7 g, 78 %).  FTIR (νmax/cm
-1),  3306, 2965, 2935, 
2875, 1689, 1635, 1538; 1H NMR (400 MHz; CDCl3) 6.83 (1H, s), 6.28 (1H, s), 5.32 (1H, s, 
NH), 5.18 (1H, s, NH), 3.55 (2H, q, J 7.0), 3.37 (4H, m), 3.24 (2H, q, J 7.0), 2.55 (2H, m), 2.43 
(4H, m), 1.55 (2H, m), 1.42 (9H, s), 0.95 (3H, t); 13C NMR (100 MHz; CDCl3) 175.6,156.0, 
79.5,37.2, 37.9,42.5, 36.1, 39.8, 23.1, 28.4, 12.0; HRMS (ES), Calculated for C14H27N3O4 
[MH+]: 302.2074, found 302.2072.  
 
Deprotected di-amide chain 20 
Boc-protected di-amide chain 19 (4.5 g, 0.016 mol) was dissolved in DCM (25 mL) and TFA 
(25 mL) added and the mixture was allowed to react for 24 hours under nitrogen. The DCM 
was removed by a rotary evaporator to give the crude product as a thick brown oil.  Water (100 
mL) was added and then removed by decantation. This washing step was repeated a further 
two times, before drying the product under a high vacuum. The crude product was dissolved in 
DCM (100 mL), and washed twice with diluted HCL (2 mL of  2M HCl diluted with 100 mL 
of water). The organic layer was dried with Mg2SO4 and the solvent removed on a rotary 
evaporator.  The product was then left to dry under a high vacuum. The crude product was 
obtained as a brown oil in a 93% yield and was used directly in the next step. FTIR (νmax/cm
-
1),  2938, 1645, 1555, 1178 and 1130; 1H NMR (400 MHz; CDCl3), 7.86 (2H, t, J 7.0), 7.75 
(2H, s), 3.26 (2H, dd, J 13.0, 7.0), 3.18 (4H, s), 2.96 (6H, m), 2.54 (2H, t, J 7.0), 2.45 (4H, m), 
1.38 (2H, m), 0.90 (3H, t, J 7.0); 13C NMR (100 MHz; CDCl3) 172.5, 170.5, 170.0, 40.5, 36.0, 








Boc-protected tyrosine chain 25 
The title compound was synthesized using the method described above for the Boc-protected 
amide chain 25, using the following; deprotected di-amide chain 20 (1.0 g, 4.98 mmol), Boc-
Tyrosine-OH (1.4 g, 4.98 mmol), DMAP (1.21 g, 9.96 mmol), triethylamine (1.52 g, 0.015 
mol) and EDC.HCl (0.78 g, 4.0 mmol).  The crude product was obtained as a pale yellow solid 
and was purified using silica chromatography with DCM (MeOH 1%) as eluent. The Boc 
product chain 25 was obtained as a white powder (1.5 g, 71%): UV (MeOH) λmax (nm) 273, 
225. FTIR (νmax/cm
-1) ,   3305, 2968, 2935, 2878, 1688, 1639, 1536, 1168; 1H NMR (400 MHz; 
MeOD) 7.04 (2H, d, J 8.5, m), 6.72 (2H, d, J 8.5), 4.18 (1H, t, J 7.0), 3.42 (4H, m), 3.15 (2H, 
t, J 7.0), 2.98 (1H, dd, J 14.0, 7.0), 2.75 (1H, dd, J 14.0, 7.0), 2.38 (2H, t, J 7.0), 2.31 (2H, q, J 
7.0), 1.55 (2H, m), 1.38 (9H, s), 0.95 (3H, t, J 7.0); 13C NMR (100 MHz; MeOD) 174.5, 173.5, 
132, 128.5, 115.5, 49.0, 41.0, 36.0, 35.0, 23.0, 28.5; MS (ES) Calculated for C23H36N4O6 [M+]: 
464, found 464 
 
Tyrosine linear chain - 3HB-LC-Tyr 26  
The title compound was synthesized using the method described above for the deprotected 
amide chain 26, using the following; Boc-protected tyrosine chain 25 (1.0 g, 2.15 mmol), DCM 
(20 mL) and TFA (10 mL).3HB LC-Tyr 26 was obtained as a white powder (510 mg, 65%).  
UV (MeOH) λmax (nm) 272, 225. FTIR (νmax/cm
-1) 3288, 3086, 2936, 1634, 1536, 1512, 1185, 
1138; 1H NMR (400 MHz; MeOD) 7.08 (2H, d, J 8.5), 6.78 (2H, d, J 8.5), 3.96 (1H, t, J 7.0), 
3.42 (4H, m), 3.15 (2H, t, J 7.0), 3.05 (1H, dd, J 14.0, 7.0), 2.95 (1H, dd, J 14.0, 7.0), 2.40 (2H, 
t, J 7.0), 2.35 (2H, q, J 7.0), 1.55 (2H, m), 0.92 (3H, t, J 7.0); 13C NMR (100 MHz; MeOD) 
173.5, 173.5, 171.0 (C=O), 133.0, 126.0, 117.0 (ArC), 60.0, 43.0, 38.0, 37.5, 37.5, 36.8, 36.5, 
24.0, 12.0, HRMS (ES), Calculated for C9H19N3O2 [MH+]: 365.2183, found 365.2189 
 
Boc-protected valine chain 27 
The title compound was synthesized and purified using the method described above for the 






mmol), Boc-Valine-OH (1.1 g, 4.98 mmol), DMAP (1.21 g, 9.96 mmol), triethylamine (1.52 
g, 0.015 mol) and EDC.HCl (0.78 g, 4.0 mmol). UV (MeOH) λmax (nm) 278, 227; FTIR 
(νmax/cm
-1) ,   2932 (N-H stretch), 1640 (C=O, stretch), 1552 (N-H, bend), 1324, 1170 and 1131 
(C-N); 1H NMR (400 MHz; MeOD), 4.55 (1H, d, J 5.5, CH), 3.45 (4H, m, CH2CH2NH2), 3.10 
(2H, t, J 7.0,CH2 CH2),  2.66 (1H, sept, CH(CH3)2), 2.40 (2H, t, J 7.0 ,CH2NH), 2.35 (2H, q J 
7.0, CH2CH2), 1.58 (2H, m, CH3CH2CH2), 1.44 (9H, s,  3x CH3), 1-0.98 (6H, d, CH(CH3)2), 
0.95 (3H, t, J 7.5, CH2CH3); 
13C NMR (100 MHz; MeOD) 173.0, 172.0, 160.5 (C=O), 80.0 
(C), 64.0, 41.0, 37.0, 34.5, 32.0 , 29.0 (CH3), 19.5  (CH3),12.0 (CH3); 72% yield ; MS (ES), 
Calculated for C19H36N4O5 [M+]: 400, found 400. 
 
Valine linear chain – 3HB-LC-Val 28 
The title compound was synthesized using the method described above for the deprotected 
amide chain 28, using the following; Boc-protected valine chain 27 (1.0 g, 2.50 mmol), DCM 
(20 mL) and TFA (10 mL). 3HBLC-Val 28 was obtained as a white powder (435 mg, 58%).  
UV (MeOH) λmax (nm) 278, 227; FTIR (νmax/cm
-1) ,   2940, 1657, 1566, 1280, 1130; 1H NMR 
(400 MHz; MeOD), 5.28 (1H, s, NH), 3.55 (1H, d, J 5.5, CH),  3.45 (4H, m, CH2CH2NH2), 
3.10 (2H, t, J 7.0,CH2CH2),  2.40 (2H, t, J 7.0 ,CH2NH), 2.35 (2H, q J 7.0, CH2CH2), 2.26 (1H, 
sept, CH(CH3)2), 1.58 (2H, m, CH3CH2CH2), 1-0.98 (6H, d, CH(CH3)2), 0.91 (3H, t, J 7.5, 
CH2CH3); 
13C NMR (100 MHz; MeOD) 172.5, 170 (C=O), 41.0, 38.0, 35.0, 32.0, 29.0 (CH2), 
18.5 (CH3),13.0 (CH3); 55% yield; HRMS (ES), Calculated for C14H28N4O3 [MH+]: 301.2234, 
found 301.2240. 
 
Tetrahydroxyphenylporphyrin – THPP  
Freshly distilled pyrrole (12.51 g, 180 mmol) and 4-hydroxylbenzaldehyde (30.0 g, 120 mmol) 
were refluxed in propionic acid (500 mL) for 24 hours. The mixture was allowed to cool to 
room temperature and left for 2 hours at -5⁰ C. The crude product precipitated and was 






ethanol. The product was collected and dried to give purple crystals.  Yield (2.0 g, 2.5%). UV 
(MeOH) λmax (nm) 418, 520, 560, 595, 655; FTIR (νmax/cm
-1) 3248, 2924,1609, 1463, 1378, 
1172, 964,798; 1H NMR (400 MHz; DMSO) 9.97 (s , 4H), 8.84 (s, 8H), 7.96(d, J 8.50 , 8H), 
7.18 (d, J 8.50 , 8H), -2.92 (s, 2H); 13C NMR (100 MHz; CDCl3) 134.5, 127.6, 126.5, 120.4, 
11.8; MS (ES), Calculated for C44H30N4O4 [MH+] 679 (MH
+), Found 679.  
Zinc tetrahydroxyphenylporphyrin – Zn-THPP 29 
THPP (2.0 g, 2.0 mmol) and an excess of zinc acetate-dihydrate (2.0g) were refluxed in 100 
mL of DCM for 10 minutes. The solution was filtered and evaporated and the crude product 
recrystallized from DCM/hexane to give Zn-THPP 29 as purple crystals in a yield of 87%.  UV 
(MeOH) λmax (nm) 425.5, 595,  660; FTIR (νmax/cm
-1) 2923, 3245, 2924,1609, 1465; 1H NMR 
(400 MHz; DMSO) 9.97 (s, 4H), 8.84 (s, 8H), 7.96 (d, J 8.50), 7.18 (d, 8H, J 8.50); 13C NMR 
(100 MHz; CDCl3) 134.5, 127.6, 126.5, 120.4, 11.8; MS (ES), Calculated for C44H28N4O4Zn  
[MH+] 743 (MH+), Found 743.  
 
Protein binding titration 
A stock solution of the macromolecular ligand was prepared by adding dendrimer, linear chain 
and Zn-THPP to methanol.  The methanol was removed and phosphate buffer (pH 7.4, 0.01M) 
was added to the resulting paste to give a solution that was 1.0 µM in dendrimer and Zn-THPP 
and 10 µM in linear chain.  For control experiments the same procedure was used, but one or 
more components were removed.  To ensure the titration was performed under constant 
concentration of Zn-THPP, the stock solution was also used as the solvent to make a 1.0 µM 
Cytochrome-c solution.  
1.5 mL of the stock solution was added to a quartz cuvette and placed into a fluorimeter.  
Aliquots of the cytochrome-c solution were then added and the intensity of the emission peak 
at 610 nm (excitation at 410 nm) monitored after each addition.  The data was plotted with 
respect to the concentration of cytochrome-c and curve fitting analysis used to fit the 
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